abs | rel | |
---|---|---|
Health | 165 | 94.8% |
Health care | 141 | 81.0% |
Medicine | 131 | 75.3% |
Risk | 93 | 53.4% |
Health sciences | 89 | 51.1% |
Disease | 84 | 48.3% |
Human activities | 74 | 42.5% |
Public health | 73 | 42.0% |
Medical specialties | 68 | 39.1% |
Infection | 64 | 36.8% |
Clinical medicine | 63 | 36.2% |
Preventive healthcare | 62 | 35.6% |
Research | 55 | 31.6% |
Health system | 54 | 31.0% |
Economy | 51 | 29.3% |
Education | 45 | 25.9% |
Economic growth | 44 | 25.3% |
Medicare (United States) | 44 | 25.3% |
Disability | 43 | 24.7% |
Epidemiology | 43 | 24.7% |
Health insurance | 42 | 24.1% |
Market (economics) | 42 | 24.1% |
Medicaid | 40 | 23.0% |
Sustainable Development Goals | 40 | 23.0% |
Insurance | 39 | 22.4% |
Sustainability | 39 | 22.4% |
Ageing | 38 | 21.8% |
Evaluation | 38 | 21.8% |
Governance | 38 | 21.8% |
Science | 38 | 21.8% |
Social exclusion | 38 | 21.8% |
Chronic condition | 37 | 21.3% |
Gender | 37 | 21.3% |
Innovation | 37 | 21.3% |
Economic inequality | 36 | 20.7% |
Health economics | 36 | 20.7% |
Infrastructure | 36 | 20.7% |
Mental health | 36 | 20.7% |
Open science | 36 | 20.7% |
Vaccine | 36 | 20.7% |
Antimicrobial resistance | 35 | 20.1% |
Computer security | 35 | 20.1% |
Digital transformation | 35 | 20.1% |
Health policy | 35 | 20.1% |
Society | 35 | 20.1% |
Technology | 35 | 20.1% |
Cloud computing | 34 | 19.5% |
Entrepreneurship | 34 | 19.5% |
Health equity | 34 | 19.5% |
Immigration | 34 | 19.5% |
Interoperability | 34 | 19.5% |
Quality of life | 34 | 19.5% |
Artificial intelligence | 33 | 19.0% |
Cultural heritage | 33 | 19.0% |
Democracy | 33 | 19.0% |
Globalization | 33 | 19.0% |
Internet of things | 33 | 19.0% |
Personalized medicine | 33 | 19.0% |
Productivity | 33 | 19.0% |
Security | 33 | 19.0% |
Climate change mitigation | 32 | 18.4% |
Cyberattack | 32 | 18.4% |
Mental disorder | 32 | 18.4% |
Privacy | 32 | 18.4% |
Circular economy | 31 | 17.8% |
Emerging technologies | 31 | 17.8% |
Expert | 31 | 17.8% |
Multiculturalism | 31 | 17.8% |
Non-communicable disease | 31 | 17.8% |
Strategic planning | 31 | 17.8% |
Substance abuse | 31 | 17.8% |
Sustainable Development Goal 9 | 31 | 17.8% |
Competition (economics) | 30 | 17.2% |
Health informatics | 30 | 17.2% |
Hospital | 30 | 17.2% |
Manufacturing | 30 | 17.2% |
Sustainable Development Goal 3 | 29 | 16.7% |
Climate change | 28 | 16.1% |
Climate resilience | 28 | 16.1% |
Computing | 28 | 16.1% |
Health technology | 28 | 16.1% |
Resource | 28 | 16.1% |
Robotics | 28 | 16.1% |
Sustainable development | 28 | 16.1% |
Digital Single Market | 27 | 15.5% |
Health promotion | 27 | 15.5% |
Medication | 27 | 15.5% |
Automation | 26 | 14.9% |
Child | 26 | 14.9% |
Opioid | 26 | 14.9% |
Substance use disorder | 26 | 14.9% |
Sustainable Development Goal 8 | 26 | 14.9% |
Culture | 25 | 14.4% |
Evidence-based medicine | 25 | 14.4% |
Human migration | 25 | 14.4% |
Politics | 25 | 14.4% |
Sustainable Development Goal 4 | 25 | 14.4% |
European Union legislative procedure | 24 | 13.8% |
Gender equality | 24 | 13.8% |
Patient Protection and Affordable Care Act | 24 | 13.8% |
Prescription drug | 24 | 13.8% |
Psychiatry | 24 | 13.8% |
Welfare | 24 | 13.8% |
COVID-19 pandemic | 23 | 13.2% |
Digital health | 23 | 13.2% |
Psychology | 23 | 13.2% |
Tax | 23 | 13.2% |
Treaty on the Functioning of the European Union | 23 | 13.2% |
Computer network | 22 | 12.6% |
Employment | 22 | 12.6% |
Human trafficking | 22 | 12.6% |
Medical diagnosis | 22 | 12.6% |
Opioid use disorder | 22 | 12.6% |
Coronavirus disease 2019 | 21 | 12.1% |
Empowerment | 21 | 12.1% |
Major depressive disorder | 21 | 12.1% |
Behavioural sciences | 19 | 10.9% |
Big data | 19 | 10.9% |
Naloxone | 19 | 10.9% |
Patient | 19 | 10.9% |
Policy | 19 | 10.9% |
Psychotherapy | 19 | 10.9% |
Sustainable Development Goal 12 | 19 | 10.9% |
Buprenorphine | 18 | 10.3% |
Drug overdose | 18 | 10.3% |
Government | 18 | 10.3% |
Health care prices in the United States | 17 | 9.8% |
Influenza | 17 | 9.8% |
Cancer | 16 | 9.2% |
Childbirth | 16 | 9.2% |
Clinical psychology | 16 | 9.2% |
Health professional | 16 | 9.2% |
Information privacy | 16 | 9.2% |
Reinsurance | 16 | 9.2% |
Sustainable Development Goal 5 | 16 | 9.2% |
Therapy | 16 | 9.2% |
Cognitive behavioral therapy | 15 | 8.6% |
Pandemic | 15 | 8.6% |
Telehealth | 15 | 8.6% |
Diseases and disorders | 14 | 8.0% |
Electronic health record | 14 | 8.0% |
Health insurance marketplace | 14 | 8.0% |
Psychiatry-related fields | 14 | 8.0% |
Screening (medicine) | 14 | 8.0% |
Caregiver | 13 | 7.5% |
Drugs | 13 | 7.5% |
Health insurance coverage in the United States | 13 | 7.5% |
Heroin | 13 | 7.5% |
Opioid epidemic in the United States | 13 | 7.5% |
Pharmacy | 13 | 7.5% |
Physical therapy | 13 | 7.5% |
Service industries | 13 | 7.5% |
Substance dependence | 13 | 7.5% |
Comorbidity | 12 | 6.9% |
Economics of service industries | 12 | 6.9% |
Low-carbon economy | 12 | 6.9% |
Maternal death | 12 | 6.9% |
Maternal health | 12 | 6.9% |
Psychoactive drugs | 12 | 6.9% |
Psychosocial | 12 | 6.9% |
Social work | 12 | 6.9% |
Affordable Care Act | 11 | 6.3% |
Contract | 11 | 6.3% |
Diagnostic and Statistical Manual of Mental Disorders | 11 | 6.3% |
Europe | 11 | 6.3% |
Fentanyl | 11 | 6.3% |
HIV/AIDS | 11 | 6.3% |
Health care in the United States | 11 | 6.3% |
Internet | 11 | 6.3% |
Materials science | 11 | 6.3% |
Opioid overdose | 11 | 6.3% |
Randomized controlled trial | 11 | 6.3% |
Risk assessment | 11 | 6.3% |
Actuarial science | 10 | 5.7% |
Alcoholism | 10 | 5.7% |
Anxiety disorder | 10 | 5.7% |
Business | 10 | 5.7% |
Depression (mood) | 10 | 5.7% |
Epidemic | 10 | 5.7% |
Medical prescription | 10 | 5.7% |
Nanoelectronics | 10 | 5.7% |
Regression analysis | 10 | 5.7% |
Systematic review | 10 | 5.7% |
Violence | 10 | 5.7% |
Abuse | 9 | 5.2% |
Antipsychotic | 9 | 5.2% |
Branches of science | 9 | 5.2% |
Clinical trial | 9 | 5.2% |
Copernicus Programme | 9 | 5.2% |
Dose (biochemistry) | 9 | 5.2% |
Emergency department | 9 | 5.2% |
Meta-analysis | 9 | 5.2% |
Methadone | 9 | 5.2% |
Nursing | 9 | 5.2% |
Pay for performance (healthcare) | 9 | 5.2% |
Pharmacology | 9 | 5.2% |
Poverty | 9 | 5.2% |
Pregnancy | 9 | 5.2% |
Psychological concepts | 9 | 5.2% |
Radicalization | 9 | 5.2% |
Social aspects of psychoactive drugs | 9 | 5.2% |
Social distancing | 9 | 5.2% |
Suicide | 9 | 5.2% |
Sustainable Development Goal 16 | 9 | 5.2% |
Abnormal psychology | 8 | 4.6% |
Accessibility | 8 | 4.6% |
Capitation (healthcare) | 8 | 4.6% |
Competition (companies) | 8 | 4.6% |
Corporate social responsibility | 8 | 4.6% |
Drug development | 8 | 4.6% |
Drug rehabilitation | 8 | 4.6% |
Drugs acting on the nervous system | 8 | 4.6% |
Economics | 8 | 4.6% |
Harm reduction | 8 | 4.6% |
Health insurance in the United States | 8 | 4.6% |
Infant | 8 | 4.6% |
Kidney transplantation | 8 | 4.6% |
Life expectancy | 8 | 4.6% |
Medical treatments | 8 | 4.6% |
Medicare Part D | 8 | 4.6% |
Natural environment | 8 | 4.6% |
Obesity | 8 | 4.6% |
Positive psychology | 8 | 4.6% |
Premium tax credit | 8 | 4.6% |
Prenatal development | 8 | 4.6% |
Pricing | 8 | 4.6% |
Severe acute respiratory syndrome coronavirus 2 | 8 | 4.6% |
Simulation | 8 | 4.6% |
Social determinants of health | 8 | 4.6% |
Synergy | 8 | 4.6% |
Adherence (medicine) | 7 | 4.0% |
Adolescence | 7 | 4.0% |
Antidepressant | 7 | 4.0% |
Bipolar disorder | 7 | 4.0% |
COVID-19 testing | 7 | 4.0% |
Cardiovascular disease | 7 | 4.0% |
Cognition | 7 | 4.0% |
Creative industries | 7 | 4.0% |
Data analysis | 7 | 4.0% |
Drug | 7 | 4.0% |
Fee-for-service | 7 | 4.0% |
Finance | 7 | 4.0% |
Financial law | 7 | 4.0% |
Financial risk | 7 | 4.0% |
Homelessness | 7 | 4.0% |
Institution | 7 | 4.0% |
Life-cycle assessment | 7 | 4.0% |
Medical guideline | 7 | 4.0% |
Mental and behavioural disorders | 7 | 4.0% |
Mortality rate | 7 | 4.0% |
Organ transplantation | 7 | 4.0% |
Pain management | 7 | 4.0% |
Pollution | 7 | 4.0% |
Prescription monitoring program | 7 | 4.0% |
Primary care | 7 | 4.0% |
Progress | 7 | 4.0% |
Psychological trauma | 7 | 4.0% |
Psychosis | 7 | 4.0% |
Public services | 7 | 4.0% |
Rebate (marketing) | 7 | 4.0% |
Social Security (United States) | 7 | 4.0% |
Social programs | 7 | 4.0% |
Social stigma | 7 | 4.0% |
Transmission (medicine) | 7 | 4.0% |
Venlafaxine | 7 | 4.0% |
Veteran | 7 | 4.0% |
Analgesic | 6 | 3.4% |
Anxiety | 6 | 3.4% |
Booster dose | 6 | 3.4% |
Committee | 6 | 3.4% |
Crisis | 6 | 3.4% |
Dementia | 6 | 3.4% |
Fee | 6 | 3.4% |
General practitioner | 6 | 3.4% |
Gross domestic product | 6 | 3.4% |
Health Insurance Portability and Accountability Act | 6 | 3.4% |
Health insurance mandate | 6 | 3.4% |
Hepatitis | 6 | 3.4% |
Medical humanities | 6 | 3.4% |
Mood disorder | 6 | 3.4% |
Neuroscience | 6 | 3.4% |
Opioid epidemic | 6 | 3.4% |
Patient safety | 6 | 3.4% |
Preterm birth | 6 | 3.4% |
Psychological resilience | 6 | 3.4% |
Public sphere | 6 | 3.4% |
Regulatory Flexibility Act | 6 | 3.4% |
Self-care | 6 | 3.4% |
Self-harm | 6 | 3.4% |
Sensitivity and specificity | 6 | 3.4% |
Sertraline | 6 | 3.4% |
Severe acute respiratory syndrome | 6 | 3.4% |
Social mobility | 6 | 3.4% |
Trade secret | 6 | 3.4% |
Adverse effect | 5 | 2.9% |
Adverse selection | 5 | 2.9% |
Attention deficit hyperactivity disorder | 5 | 2.9% |
Basic reproduction number | 5 | 2.9% |
Blinded experiment | 5 | 2.9% |
Community health | 5 | 2.9% |
Copayment | 5 | 2.9% |
Correlation and dependence | 5 | 2.9% |
Crisis management | 5 | 2.9% |
Errors and residuals | 5 | 2.9% |
Financial services | 5 | 2.9% |
Generic drug | 5 | 2.9% |
Health care industry | 5 | 2.9% |
Human reproduction | 5 | 2.9% |
Infant mortality | 5 | 2.9% |
Influenza pandemic | 5 | 2.9% |
Influenza vaccine | 5 | 2.9% |
Labour economics | 5 | 2.9% |
Managed care | 5 | 2.9% |
Management of HIV/AIDS | 5 | 2.9% |
Medical test | 5 | 2.9% |
Medicare Advantage | 5 | 2.9% |
Middle East respiratory syndrome | 5 | 2.9% |
Neonatal withdrawal | 5 | 2.9% |
Out-of-pocket expense | 5 | 2.9% |
Pain | 5 | 2.9% |
Peer review | 5 | 2.9% |
Pharmaceutical sciences | 5 | 2.9% |
Physician | 5 | 2.9% |
Posttraumatic stress disorder | 5 | 2.9% |
Prenatal care | 5 | 2.9% |
Pro rata | 5 | 2.9% |
Psychiatric and mental health nursing | 5 | 2.9% |
Psychiatric diagnosis | 5 | 2.9% |
Public policy | 5 | 2.9% |
Quarantine | 5 | 2.9% |
Recession | 5 | 2.9% |
Recovery model | 5 | 2.9% |
Schizophrenia | 5 | 2.9% |
Selective serotonin reuptake inhibitor | 5 | 2.9% |
Social inequality | 5 | 2.9% |
Statistics | 5 | 2.9% |
Subsidy | 5 | 2.9% |
Tax credit | 5 | 2.9% |
Temporary Assistance for Needy Families | 5 | 2.9% |
Traumatic brain injury | 5 | 2.9% |
Woman | 5 | 2.9% |
Applied psychology | 4 | 2.3% |
Bias | 4 | 2.3% |
Breastfeeding | 4 | 2.3% |
COVID-19 pandemic in the United Kingdom | 4 | 2.3% |
Child abuse | 4 | 2.3% |
Community mental health service | 4 | 2.3% |
Compartmental models in epidemiology | 4 | 2.3% |
Competition | 4 | 2.3% |
Confidence interval | 4 | 2.3% |
Confidentiality | 4 | 2.3% |
Digital twin | 4 | 2.3% |
Emergency management | 4 | 2.3% |
Gabapentin | 4 | 2.3% |
Global health | 4 | 2.3% |
Human diseases and disorders | 4 | 2.3% |
Hypertension | 4 | 2.3% |
Immunization | 4 | 2.3% |
Immunology | 4 | 2.3% |
Income | 4 | 2.3% |
Intensive care medicine | 4 | 2.3% |
Intensive care unit | 4 | 2.3% |
Macroeconomics | 4 | 2.3% |
Morphine | 4 | 2.3% |
Motherhood | 4 | 2.3% |
Naltrexone | 4 | 2.3% |
Neurology | 4 | 2.3% |
Open access | 4 | 2.3% |
Opiate | 4 | 2.3% |
Oxycodone | 4 | 2.3% |
Parental leave | 4 | 2.3% |
Parenting | 4 | 2.3% |
Pharmaceutical industry | 4 | 2.3% |
Photonics | 4 | 2.3% |
Post-traumatic stress disorder | 4 | 2.3% |
Postpartum period | 4 | 2.3% |
Poverty in the United States | 4 | 2.3% |
Pre-existing condition | 4 | 2.3% |
Prediction | 4 | 2.3% |
Price | 4 | 2.3% |
Psychiatric hospital | 4 | 2.3% |
Psychopathology | 4 | 2.3% |
Public hospital | 4 | 2.3% |
Recovery approach | 4 | 2.3% |
Retirement | 4 | 2.3% |
Risk management | 4 | 2.3% |
Sick leave | 4 | 2.3% |
Social innovation | 4 | 2.3% |
Software | 4 | 2.3% |
Spanish flu | 4 | 2.3% |
Suicide prevention | 4 | 2.3% |
Sustainable Development Goal 13 | 4 | 2.3% |
Weighted arithmetic mean | 4 | 2.3% |
Women's health | 4 | 2.3% |
Zoonosis | 4 | 2.3% |
21st Century Cures Act | 3 | 1.7% |
Accountable care organization | 3 | 1.7% |
Addiction | 3 | 1.7% |
Amitriptyline | 3 | 1.7% |
Asplenia | 3 | 1.7% |
Bank | 3 | 1.7% |
Behaviour therapy | 3 | 1.7% |
Benzodiazepine | 3 | 1.7% |
Biosimilar | 3 | 1.7% |
Borderline personality disorder | 3 | 1.7% |
COVID-19 | 3 | 1.7% |
COVID-19 vaccine | 3 | 1.7% |
Cannabis (drug) | 3 | 1.7% |
Care in the Community | 3 | 1.7% |
Census | 3 | 1.7% |
Childhood immunizations in the United States | 3 | 1.7% |
Children's Health Insurance Program | 3 | 1.7% |
Chronic obstructive pulmonary disease | 3 | 1.7% |
Cognitive disorder | 3 | 1.7% |
Community health worker | 3 | 1.7% |
Confounding | 3 | 1.7% |
Consumer price index | 3 | 1.7% |
Contact tracing | 3 | 1.7% |
Cost | 3 | 1.7% |
Cyber-physical system | 3 | 1.7% |
Cybercrime | 3 | 1.7% |
Death | 3 | 1.7% |
Dependent and independent variables | 3 | 1.7% |
Disability-adjusted life year | 3 | 1.7% |
Disease burden | 3 | 1.7% |
Drug withdrawal | 3 | 1.7% |
Dual diagnosis | 3 | 1.7% |
Educational technology | 3 | 1.7% |
Effect size | 3 | 1.7% |
Epilepsy | 3 | 1.7% |
Executive Order 12866 | 3 | 1.7% |
General medical services | 3 | 1.7% |
HIV-associated neurocognitive disorder | 3 | 1.7% |
Haemophilus influenzae | 3 | 1.7% |
Health and politics | 3 | 1.7% |
Health data | 3 | 1.7% |
Health literacy | 3 | 1.7% |
Herd immunity | 3 | 1.7% |
Human development | 3 | 1.7% |
Human nature | 3 | 1.7% |
Illegal drug trade | 3 | 1.7% |
Impulsivity | 3 | 1.7% |
Influenza A virus subtype H1N1 | 3 | 1.7% |
Information | 3 | 1.7% |
Interpersonal psychotherapy | 3 | 1.7% |
K-Quarantine | 3 | 1.7% |
Liver transplantation | 3 | 1.7% |
Management of depression | 3 | 1.7% |
Mental distress | 3 | 1.7% |
Methylphenidate | 3 | 1.7% |
Natural disaster | 3 | 1.7% |
New Deal | 3 | 1.7% |
Non-governmental organization | 3 | 1.7% |
Nurse practitioner | 3 | 1.7% |
Office of Inspector General (United States) | 3 | 1.7% |
Option (finance) | 3 | 1.7% |
Ordinary least squares | 3 | 1.7% |
Organ donation | 3 | 1.7% |
PHQ-9 | 3 | 1.7% |
Pearson correlation coefficient | 3 | 1.7% |
Peer support | 3 | 1.7% |
Pension | 3 | 1.7% |
Percentage | 3 | 1.7% |
Pharmacy benefit management | 3 | 1.7% |
Pneumococcal conjugate vaccine | 3 | 1.7% |
Pneumococcal vaccine | 3 | 1.7% |
Positive and negative predictive values | 3 | 1.7% |
Pre-exposure prophylaxis | 3 | 1.7% |
Prevention of HIV/AIDS | 3 | 1.7% |
Primary health care | 3 | 1.7% |
Prison | 3 | 1.7% |
Procurement | 3 | 1.7% |
Psychiatric assessment | 3 | 1.7% |
Psychiatrist | 3 | 1.7% |
Quality and Outcomes Framework | 3 | 1.7% |
Reporting bias | 3 | 1.7% |
Reproductive health | 3 | 1.7% |
Research and development | 3 | 1.7% |
Residency (medicine) | 3 | 1.7% |
Respiratory disease | 3 | 1.7% |
Right to know | 3 | 1.7% |
Sex work | 3 | 1.7% |
Sex worker | 3 | 1.7% |
Social issues | 3 | 1.7% |
Somatic symptom disorder | 3 | 1.7% |
Strategy | 3 | 1.7% |
Survey methodology | 3 | 1.7% |
Telecommuting | 3 | 1.7% |
The Path to Prosperity | 3 | 1.7% |
Trazodone | 3 | 1.7% |
Tuberculosis | 3 | 1.7% |
Unfunded mandate | 3 | 1.7% |
United States Consumer Price Index | 3 | 1.7% |
Universal health care | 3 | 1.7% |
Vaccination schedule | 3 | 1.7% |
WIC | 3 | 1.7% |
Youth | 3 | 1.7% |
Acne | 2 | 1.1% |
Actuary | 2 | 1.1% |
Advanced practice nurse | 2 | 1.1% |
Agoraphobia | 2 | 1.1% |
Audit | 2 | 1.1% |
Autism | 2 | 1.1% |
Autism spectrum | 2 | 1.1% |
Avian influenza | 2 | 1.1% |
BRCA mutation | 2 | 1.1% |
Behavior | 2 | 1.1% |
Benzoyl peroxide/clindamycin | 2 | 1.1% |
Best practice | 2 | 1.1% |
Birth control | 2 | 1.1% |
Birth defect | 2 | 1.1% |
Bond (finance) | 2 | 1.1% |
Budget of the European Union | 2 | 1.1% |
Caesarean section | 2 | 1.1% |
Carfentanil | 2 | 1.1% |
Centrality | 2 | 1.1% |
Chatbot | 2 | 1.1% |
Chemicals in medicine | 2 | 1.1% |
Child support | 2 | 1.1% |
Chronic pain | 2 | 1.1% |
Citalopram | 2 | 1.1% |
Clinic | 2 | 1.1% |
Clonidine | 2 | 1.1% |
Coefficient of determination | 2 | 1.1% |
Cognitive science | 2 | 1.1% |
Cohort study | 2 | 1.1% |
Collaboration | 2 | 1.1% |
Counterfeit consumer goods | 2 | 1.1% |
Creative Commons license | 2 | 1.1% |
Critical thinking | 2 | 1.1% |
DSM-5 | 2 | 1.1% |
David Shulkin | 2 | 1.1% |
Deductible | 2 | 1.1% |
Demand | 2 | 1.1% |
Demography | 2 | 1.1% |
Development aid | 2 | 1.1% |
Diabetes mellitus | 2 | 1.1% |
Diagnosis of schizophrenia | 2 | 1.1% |
Digital literacy | 2 | 1.1% |
Disease surveillance | 2 | 1.1% |
Economic development | 2 | 1.1% |
Economic equilibrium | 2 | 1.1% |
Education in France | 2 | 1.1% |
Electroconvulsive therapy | 2 | 1.1% |
Emergency | 2 | 1.1% |
Ethics | 2 | 1.1% |
Exponential distribution | 2 | 1.1% |
Extended-release morphine | 2 | 1.1% |
Eye movement desensitization and reprocessing | 2 | 1.1% |
False positives and false negatives | 2 | 1.1% |
Financial crisis of 2007–2008 | 2 | 1.1% |
Fixed effects model | 2 | 1.1% |
Fluoxetine | 2 | 1.1% |
Forecasting | 2 | 1.1% |
Foster care | 2 | 1.1% |
Generalized anxiety disorder | 2 | 1.1% |
Gestational age | 2 | 1.1% |
Great Depression | 2 | 1.1% |
Greenhouse gas | 2 | 1.1% |
Gyeongsang Province | 2 | 1.1% |
HIV/AIDS in Africa | 2 | 1.1% |
Hazard | 2 | 1.1% |
Health care reform | 2 | 1.1% |
Health security | 2 | 1.1% |
Health technology in the United States | 2 | 1.1% |
Healthcare in Taiwan | 2 | 1.1% |
Hospital bed | 2 | 1.1% |
Hospital readmission | 2 | 1.1% |
Human pregnancy | 2 | 1.1% |
Hypertensive disease of pregnancy | 2 | 1.1% |
Imputation (statistics) | 2 | 1.1% |
Incentive | 2 | 1.1% |
Income tax in the United States | 2 | 1.1% |
Individual and political action on climate change | 2 | 1.1% |
Influenza A virus subtype H3N2 | 2 | 1.1% |
Influenza A virus subtype H5N1 | 2 | 1.1% |
Intellectual disability | 2 | 1.1% |
Interest | 2 | 1.1% |
Interest rate | 2 | 1.1% |
International Classification of Diseases | 2 | 1.1% |
International Health Regulations | 2 | 1.1% |
Intervention (counseling) | 2 | 1.1% |
Isolation (health care) | 2 | 1.1% |
Kidney failure | 2 | 1.1% |
Korea | 2 | 1.1% |
Learning | 2 | 1.1% |
Learning disability | 2 | 1.1% |
Learning management system | 2 | 1.1% |
Liability insurance | 2 | 1.1% |
Licensure | 2 | 1.1% |
Likelihood function | 2 | 1.1% |
Linear regression | 2 | 1.1% |
Loss ratio | 2 | 1.1% |
Mania | 2 | 1.1% |
Market liquidity | 2 | 1.1% |
Medical home | 2 | 1.1% |
Mental Health Act 1983 | 2 | 1.1% |
Methadone maintenance | 2 | 1.1% |
Midwife | 2 | 1.1% |
Military sexual trauma | 2 | 1.1% |
Moclobemide | 2 | 1.1% |
Monoamine oxidase inhibitor | 2 | 1.1% |
Mother | 2 | 1.1% |
Motivational interviewing | 2 | 1.1% |
Multistakeholder governance | 2 | 1.1% |
Nancy Pelosi | 2 | 1.1% |
Neonatal intensive care unit | 2 | 1.1% |
Nervous system | 2 | 1.1% |
Neuromorphic engineering | 2 | 1.1% |
Newborn screening | 2 | 1.1% |
Obstetrics | 2 | 1.1% |
Organization | 2 | 1.1% |
Organized crime | 2 | 1.1% |
Outcomes research | 2 | 1.1% |
P-value | 2 | 1.1% |
Panic attack | 2 | 1.1% |
Parameter | 2 | 1.1% |
Participatory design | 2 | 1.1% |
Personal protective equipment | 2 | 1.1% |
Personality disorder | 2 | 1.1% |
Phenobarbital | 2 | 1.1% |
Phobia | 2 | 1.1% |
Physical examination | 2 | 1.1% |
Placebo | 2 | 1.1% |
Pledge of Allegiance | 2 | 1.1% |
Pneumonia | 2 | 1.1% |
Police dog | 2 | 1.1% |
Polymerase chain reaction | 2 | 1.1% |
Population health | 2 | 1.1% |
Pre-eclampsia | 2 | 1.1% |
Precarity | 2 | 1.1% |
Prescription drug prices in the United States | 2 | 1.1% |
Profit (economics) | 2 | 1.1% |
Project Bioshield Act | 2 | 1.1% |
Pseudoephedrine | 2 | 1.1% |
Psychiatric diseases and disorders | 2 | 1.1% |
Psychiatric rehabilitation | 2 | 1.1% |
Public–private partnership | 2 | 1.1% |
Race (human categorization) | 2 | 1.1% |
Race and ethnicity in the United States Census | 2 | 1.1% |
Receiver operating characteristic | 2 | 1.1% |
Reconciliation (United States Congress) | 2 | 1.1% |
Recruitment | 2 | 1.1% |
Reference range | 2 | 1.1% |
Registered nurse | 2 | 1.1% |
Reliability (statistics) | 2 | 1.1% |
Sampling (statistics) | 2 | 1.1% |
Schizoaffective disorder | 2 | 1.1% |
School | 2 | 1.1% |
School voucher | 2 | 1.1% |
Screening, brief intervention and referral to treatment | 2 | 1.1% |
Self-insurance | 2 | 1.1% |
Serology | 2 | 1.1% |
Services sector of the economy | 2 | 1.1% |
Sibling | 2 | 1.1% |
Signs and symptoms | 2 | 1.1% |
Single-payer healthcare | 2 | 1.1% |
Social constructionism | 2 | 1.1% |
Socioeconomic status | 2 | 1.1% |
South Korean won | 2 | 1.1% |
Spearman's rank correlation coefficient | 2 | 1.1% |
Specialty drugs in the United States | 2 | 1.1% |
States of emergency in France | 2 | 1.1% |
Stimulant | 2 | 1.1% |
Stress (biology) | 2 | 1.1% |
Stressor | 2 | 1.1% |
Stroke | 2 | 1.1% |
Substance-related disorders | 2 | 1.1% |
Supplemental Nutrition Assistance Program | 2 | 1.1% |
Supplemental Security Income | 2 | 1.1% |
Sustainable Development Goal 1 | 2 | 1.1% |
Sustainable Development Goal 7 | 2 | 1.1% |
Sustainable energy | 2 | 1.1% |
Symptom | 2 | 1.1% |
Teacher | 2 | 1.1% |
Title X | 2 | 1.1% |
Tricyclic antidepressant | 2 | 1.1% |
Type 2 diabetes | 2 | 1.1% |
United States Senate Homeland Security Permanent Subcommittee on Investigations | 2 | 1.1% |
Urinary incontinence | 2 | 1.1% |
Utilization management | 2 | 1.1% |
Vaccination | 2 | 1.1% |
Validity (statistics) | 2 | 1.1% |
Veterans' Access to Care through Choice, Accountability, and Transparency Act of 2014 | 2 | 1.1% |
Workers' compensation | 2 | 1.1% |
Worksheet | 2 | 1.1% |
2009 swine flu pandemic | 1 | 0.6% |
2019–20 coronavirus outbreak | 1 | 0.6% |
2019–20 coronavirus pandemic | 1 | 0.6% |
2020 | 1 | 0.6% |
API | 1 | 0.6% |
Abortion | 1 | 0.6% |
Absenteeism | 1 | 0.6% |
Abstinence | 1 | 0.6% |
Academic degree | 1 | 0.6% |
Active surveillance of prostate cancer | 1 | 0.6% |
Activities of daily living | 1 | 0.6% |
Adapalene | 1 | 0.6% |
Adolescent health | 1 | 0.6% |
Adult | 1 | 0.6% |
Adult attention deficit hyperactivity disorder | 1 | 0.6% |
African Americans | 1 | 0.6% |
Aggregate demand | 1 | 0.6% |
Agriculture | 1 | 0.6% |
Air pollution | 1 | 0.6% |
Alcohol abuse | 1 | 0.6% |
Alcoholic drink | 1 | 0.6% |
Alex Azar | 1 | 0.6% |
Alprazolam | 1 | 0.6% |
Analytics | 1 | 0.6% |
Anesthesia | 1 | 0.6% |
Anti-social behaviour | 1 | 0.6% |
Anticonvulsant | 1 | 0.6% |
Antisocial personality disorder | 1 | 0.6% |
Anxiety disorders | 1 | 0.6% |
Applied mathematics | 1 | 0.6% |
Arrhythmia | 1 | 0.6% |
Artificial neural network | 1 | 0.6% |
Asperger syndrome | 1 | 0.6% |
Assertive community treatment | 1 | 0.6% |
Asthma | 1 | 0.6% |
Asylum seeker | 1 | 0.6% |
Atomoxetine | 1 | 0.6% |
Attachment theory | 1 | 0.6% |
Attention deficit hyperactivity disorder management | 1 | 0.6% |
Attention deficit hyperactivity disorder predominantly inattentive | 1 | 0.6% |
Average | 1 | 0.6% |
Balance of payments | 1 | 0.6% |
Baseline (budgeting) | 1 | 0.6% |
Basic needs | 1 | 0.6% |
Benzodiazepine withdrawal syndrome | 1 | 0.6% |
Benzoyl peroxide | 1 | 0.6% |
Bill (law) | 1 | 0.6% |
Biodiversity | 1 | 0.6% |
Biomarker | 1 | 0.6% |
Birth weight | 1 | 0.6% |
Black people | 1 | 0.6% |
Blood pressure | 1 | 0.6% |
Body mass index | 1 | 0.6% |
British Bangladeshis | 1 | 0.6% |
British Pakistanis | 1 | 0.6% |
Broker | 1 | 0.6% |
Bronchiectasis | 1 | 0.6% |
COVID-19 lockdowns | 1 | 0.6% |
COVID-19 pandemic in Mexico | 1 | 0.6% |
COVID-19 pandemic in mainland China | 1 | 0.6% |
COVID-19 pandemic in the United States | 1 | 0.6% |
COVID-19 vaccination in Malaysia | 1 | 0.6% |
Cannabis | 1 | 0.6% |
Cannabis use disorder | 1 | 0.6% |
Carbon dioxide | 1 | 0.6% |
Carbon neutrality | 1 | 0.6% |
Cardiac arrest | 1 | 0.6% |
Cardiology | 1 | 0.6% |
Care work | 1 | 0.6% |
Case management (US healthcare system) | 1 | 0.6% |
Case management (mental health) | 1 | 0.6% |
Causes of death | 1 | 0.6% |
Charity care | 1 | 0.6% |
Child care | 1 | 0.6% |
Child development | 1 | 0.6% |
Child mortality | 1 | 0.6% |
Childhood | 1 | 0.6% |
Childhood psychiatric disorders | 1 | 0.6% |
Chinese nobility | 1 | 0.6% |
Choice architecture | 1 | 0.6% |
Chronic fatigue syndrome | 1 | 0.6% |
Classification of ethnicity in the United Kingdom | 1 | 0.6% |
Classification of mental disorders | 1 | 0.6% |
Cleft lip and cleft palate | 1 | 0.6% |
Climate change adaptation | 1 | 0.6% |
Clinical supervision | 1 | 0.6% |
Clomipramine | 1 | 0.6% |
Clonazepam | 1 | 0.6% |
Clozapine | 1 | 0.6% |
Codeine | 1 | 0.6% |
Colorectal cancer | 1 | 0.6% |
Combat stress reaction | 1 | 0.6% |
Comedo | 1 | 0.6% |
Community | 1 | 0.6% |
Comparative effectiveness research | 1 | 0.6% |
Compulsive behavior | 1 | 0.6% |
Computer simulation | 1 | 0.6% |
Concussion | 1 | 0.6% |
Consent | 1 | 0.6% |
Content validity | 1 | 0.6% |
Contingency management | 1 | 0.6% |
Convidecia | 1 | 0.6% |
Convolutional neural network | 1 | 0.6% |
Copyright | 1 | 0.6% |
CoronaVac | 1 | 0.6% |
Coronary artery disease | 1 | 0.6% |
Coronavirus | 1 | 0.6% |
Correlation | 1 | 0.6% |
Cost of living | 1 | 0.6% |
Cost-effectiveness analysis | 1 | 0.6% |
Cost–benefit analysis | 1 | 0.6% |
Cousin | 1 | 0.6% |
Covaxin | 1 | 0.6% |
Creativity | 1 | 0.6% |
Credit | 1 | 0.6% |
Cronbach's alpha | 1 | 0.6% |
Current Procedural Terminology | 1 | 0.6% |
Customs | 1 | 0.6% |
Cyber-security regulation | 1 | 0.6% |
Cyberwarfare | 1 | 0.6% |
Data | 1 | 0.6% |
Data and information visualization | 1 | 0.6% |
Database | 1 | 0.6% |
Debriefing | 1 | 0.6% |
Debt | 1 | 0.6% |
Deep learning | 1 | 0.6% |
Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury | 1 | 0.6% |
Defined benefit pension plan | 1 | 0.6% |
Defined contribution plan | 1 | 0.6% |
Delirium | 1 | 0.6% |
Density | 1 | 0.6% |
Dental hygienist | 1 | 0.6% |
Dental therapist | 1 | 0.6% |
Dentist | 1 | 0.6% |
Dentistry | 1 | 0.6% |
Denver Developmental Screening Tests | 1 | 0.6% |
Design | 1 | 0.6% |
Designer drug | 1 | 0.6% |
Determinants of health | 1 | 0.6% |
Developed country | 1 | 0.6% |
Developing country | 1 | 0.6% |
Developmental disabilities | 1 | 0.6% |
Developmental disability | 1 | 0.6% |
Dextroamphetamine | 1 | 0.6% |
Diabetes | 1 | 0.6% |
Diabetes mellitus type 2 | 1 | 0.6% |
Dialectical behavior therapy | 1 | 0.6% |
Dialysis | 1 | 0.6% |
Diazepam | 1 | 0.6% |
Dietary supplement | 1 | 0.6% |
Dietitian | 1 | 0.6% |
Digital contact tracing | 1 | 0.6% |
Digitization | 1 | 0.6% |
Discrimination | 1 | 0.6% |
Disease outbreak | 1 | 0.6% |
Disorders of psychological development | 1 | 0.6% |
Dispatcher | 1 | 0.6% |
Disproportionate share hospital | 1 | 0.6% |
Doctor of Medicine | 1 | 0.6% |
Donald Trump | 1 | 0.6% |
Dopamine | 1 | 0.6% |
Dopamine hypothesis of schizophrenia | 1 | 0.6% |
Drug injection | 1 | 0.6% |
Drug test | 1 | 0.6% |
Drug utilization review | 1 | 0.6% |
Dyskinesia | 1 | 0.6% |
Dysthymia | 1 | 0.6% |
Early intervention in psychosis | 1 | 0.6% |
Ebola | 1 | 0.6% |
Eclampsia | 1 | 0.6% |
Econometrics | 1 | 0.6% |
Economic recovery | 1 | 0.6% |
Economy of the United States | 1 | 0.6% |
Educational psychology | 1 | 0.6% |
Efficient energy use | 1 | 0.6% |
Eigenvalues and eigenvectors | 1 | 0.6% |
Elasticity (economics) | 1 | 0.6% |
Electronic cigarette | 1 | 0.6% |
Emergency Use Authorization | 1 | 0.6% |
Emergency medicine | 1 | 0.6% |
Emerging market | 1 | 0.6% |
Emotion | 1 | 0.6% |
Emotional dysregulation | 1 | 0.6% |
Emotions | 1 | 0.6% |
Employee benefits | 1 | 0.6% |
Empowering Patients First Act | 1 | 0.6% |
Engineering | 1 | 0.6% |
Environmental, social and corporate governance | 1 | 0.6% |
Epidemiology of HIV/AIDS | 1 | 0.6% |
Epileptic seizure | 1 | 0.6% |
Essential health benefits | 1 | 0.6% |
Ethnic group | 1 | 0.6% |
Eviction | 1 | 0.6% |
Executive Order 13813 | 1 | 0.6% |
Exercise | 1 | 0.6% |
Exploratory factor analysis | 1 | 0.6% |
Face masks during the COVID-19 pandemic | 1 | 0.6% |
Factor analysis | 1 | 0.6% |
Fair Labor Standards Act of 1938 | 1 | 0.6% |
Fall prevention | 1 | 0.6% |
Families First Coronavirus Response Act | 1 | 0.6% |
Family and Medical Leave Act of 1993 | 1 | 0.6% |
Family planning | 1 | 0.6% |
Federal Employees Health Benefits Program | 1 | 0.6% |
Federal Food, Drug, and Cosmetic Act | 1 | 0.6% |
Federally Qualified Health Center | 1 | 0.6% |
Fetal alcohol spectrum disorder | 1 | 0.6% |
Fetus | 1 | 0.6% |
Fever | 1 | 0.6% |
Fibromyalgia | 1 | 0.6% |
Fiscal policy | 1 | 0.6% |
Food | 1 | 0.6% |
Food safety | 1 | 0.6% |
Foreclosure | 1 | 0.6% |
Formulary (pharmacy) | 1 | 0.6% |
Gabapentinoid | 1 | 0.6% |
Gender pay gap | 1 | 0.6% |
Geographic information system | 1 | 0.6% |
Geographic mobility | 1 | 0.6% |
Geomatics | 1 | 0.6% |
Geriatrics | 1 | 0.6% |
Gestational diabetes | 1 | 0.6% |
Global Outbreak Alert and Response Network | 1 | 0.6% |
Global mental health | 1 | 0.6% |
Global warming | 1 | 0.6% |
Grammatical gender | 1 | 0.6% |
Grandparent | 1 | 0.6% |
Great Recession | 1 | 0.6% |
Greenland ice sheet | 1 | 0.6% |
Group insurance | 1 | 0.6% |
Guanfacine | 1 | 0.6% |
Gynaecology | 1 | 0.6% |
Haloperidol | 1 | 0.6% |
Hazard ratio | 1 | 0.6% |
Headache | 1 | 0.6% |
Healthcare | 1 | 0.6% |
Healthcare Cost and Utilization Project | 1 | 0.6% |
Healthcare in the Netherlands | 1 | 0.6% |
Healthcare industry | 1 | 0.6% |
Healthcare reform in the United States | 1 | 0.6% |
Heart | 1 | 0.6% |
Heart rate | 1 | 0.6% |
Hepatitis B | 1 | 0.6% |
Hepatitis C | 1 | 0.6% |
Hepatocellular carcinoma | 1 | 0.6% |
High-risk pregnancy | 1 | 0.6% |
Hispanic and Latino Americans | 1 | 0.6% |
Home birth | 1 | 0.6% |
Home care in the United States | 1 | 0.6% |
Horsepower | 1 | 0.6% |
Hydrocodone | 1 | 0.6% |
Hygiene | 1 | 0.6% |
Hypnotic | 1 | 0.6% |
Hypotension | 1 | 0.6% |
Improving Access to Psychological Therapies | 1 | 0.6% |
Incarceration in the United States | 1 | 0.6% |
Incidence (epidemiology) | 1 | 0.6% |
Inclusion (education) | 1 | 0.6% |
Income distribution | 1 | 0.6% |
Individual retirement account | 1 | 0.6% |
Industry | 1 | 0.6% |
Infection prevention and control | 1 | 0.6% |
Infectious diseases | 1 | 0.6% |
Influenza research | 1 | 0.6% |
Insomnia | 1 | 0.6% |
Institutional racism | 1 | 0.6% |
Institutional review board | 1 | 0.6% |
Instrumental variables estimation | 1 | 0.6% |
Insurance policy | 1 | 0.6% |
Intelligence quotient | 1 | 0.6% |
Intention-to-treat analysis | 1 | 0.6% |
International Statistical Classification of Diseases and Related Health Problems | 1 | 0.6% |
Internship (medicine) | 1 | 0.6% |
Intrauterine device | 1 | 0.6% |
Issues in ethics | 1 | 0.6% |
Janssen COVID-19 vaccine | 1 | 0.6% |
Kathleen Sebelius | 1 | 0.6% |
Ketamine | 1 | 0.6% |
Kuder–Richardson Formula 20 | 1 | 0.6% |
Landlord | 1 | 0.6% |
Large for gestational age | 1 | 0.6% |
Latin America | 1 | 0.6% |
Law | 1 | 0.6% |
Lease | 1 | 0.6% |
Least squares | 1 | 0.6% |
Licensed professional counselor | 1 | 0.6% |
Life sciences | 1 | 0.6% |
Likelihood ratios in diagnostic testing | 1 | 0.6% |
Likert scale | 1 | 0.6% |
Lineage B.1.1.7 | 1 | 0.6% |
Liquor | 1 | 0.6% |
Lisdexamfetamine | 1 | 0.6% |
Lithium (medication) | 1 | 0.6% |
Logistic regression | 1 | 0.6% |
Long COVID | 1 | 0.6% |
Long-acting reversible contraception | 1 | 0.6% |
Lorazepam | 1 | 0.6% |
Low back pain | 1 | 0.6% |
Low birth weight | 1 | 0.6% |
MDMA | 1 | 0.6% |
MEDLINE | 1 | 0.6% |
Machine learning | 1 | 0.6% |
1 | 0.6% | |
Management of schizophrenia | 1 | 0.6% |
Master of Social Work | 1 | 0.6% |
Maternal mortality in the United States | 1 | 0.6% |
Maternal–fetal medicine | 1 | 0.6% |
Mathematical modelling of infectious disease | 1 | 0.6% |
Mathematical optimization | 1 | 0.6% |
Medi-Cal | 1 | 0.6% |
Median | 1 | 0.6% |
Medical cannabis | 1 | 0.6% |
Medical record | 1 | 0.6% |
Medical research | 1 | 0.6% |
Medical statistics | 1 | 0.6% |
Medicinal chemistry | 1 | 0.6% |
Medigap | 1 | 0.6% |
Mental disorders | 1 | 0.6% |
Mental health nursing | 1 | 0.6% |
Mental health professional | 1 | 0.6% |
Metabolic syndrome | 1 | 0.6% |
Methamphetamine | 1 | 0.6% |
Middle East respiratory syndrome-related coronavirus | 1 | 0.6% |
Midwifery | 1 | 0.6% |
Migraine | 1 | 0.6% |
Minimum wage | 1 | 0.6% |
Mirtazapine | 1 | 0.6% |
Moderna COVID-19 vaccine | 1 | 0.6% |
Molecular diagnostics | 1 | 0.6% |
Monetary policy | 1 | 0.6% |
Moral hazard | 1 | 0.6% |
Motion (parliamentary procedure) | 1 | 0.6% |
Motivation | 1 | 0.6% |
Multicollinearity | 1 | 0.6% |
Multisystem inflammatory syndrome in children | 1 | 0.6% |
NHS foundation trust | 1 | 0.6% |
National Council Licensure Examination | 1 | 0.6% |
National Flood Insurance Program | 1 | 0.6% |
National Provider Identifier | 1 | 0.6% |
Nature-based solutions | 1 | 0.6% |
Needle and syringe programmes | 1 | 0.6% |
Needs assessment | 1 | 0.6% |
Neonatology | 1 | 0.6% |
Neurological disorder | 1 | 0.6% |
Neurotic, stress-related and somatoform disorders | 1 | 0.6% |
Numeracy | 1 | 0.6% |
Nursing home | 1 | 0.6% |
Nursing home care | 1 | 0.6% |
Obsessive–compulsive disorder | 1 | 0.6% |
Obstetrical bleeding | 1 | 0.6% |
Occupational safety and health | 1 | 0.6% |
Occupational therapy | 1 | 0.6% |
Odds ratio | 1 | 0.6% |
Open innovation | 1 | 0.6% |
Opioid tapering | 1 | 0.6% |
Opioid withdrawal | 1 | 0.6% |
Opium | 1 | 0.6% |
Osteoarthritis | 1 | 0.6% |
Osteopathy | 1 | 0.6% |
Over-the-counter drug | 1 | 0.6% |
Oxfordshire | 1 | 0.6% |
Oxford–AstraZeneca COVID-19 vaccine | 1 | 0.6% |
PID controller | 1 | 0.6% |
Palpitations | 1 | 0.6% |
Panic disorder | 1 | 0.6% |
Parent | 1 | 0.6% |
Paris Agreement | 1 | 0.6% |
Paroxetine | 1 | 0.6% |
Partial correlation | 1 | 0.6% |
Patient participation | 1 | 0.6% |
Percentile | 1 | 0.6% |
Perfect competition | 1 | 0.6% |
Peripheral neuropathy | 1 | 0.6% |
Pervasive developmental disorder | 1 | 0.6% |
Pervasive developmental disorders | 1 | 0.6% |
Pesticide | 1 | 0.6% |
Pfizer–BioNTech COVID-19 vaccine | 1 | 0.6% |
Pharmacist | 1 | 0.6% |
Physical fitness | 1 | 0.6% |
Physician assistant | 1 | 0.6% |
Pimple | 1 | 0.6% |
Plague of Justinian | 1 | 0.6% |
Planetary boundaries | 1 | 0.6% |
Poly drug use | 1 | 0.6% |
Pool Re | 1 | 0.6% |
Population | 1 | 0.6% |
Postpartum depression | 1 | 0.6% |
Poverty threshold | 1 | 0.6% |
Powered air-purifying respirator | 1 | 0.6% |
Precipitation | 1 | 0.6% |
Precision and recall | 1 | 0.6% |
Precision medicine | 1 | 0.6% |
Prevalence | 1 | 0.6% |
Price elasticity of demand | 1 | 0.6% |
Primary healthcare | 1 | 0.6% |
Principal component analysis | 1 | 0.6% |
Prohibition | 1 | 0.6% |
Prohibition of drugs | 1 | 0.6% |
Prostate cancer | 1 | 0.6% |
Provinces and territories of Canada | 1 | 0.6% |
Psychoactive drug | 1 | 0.6% |
Psychological evaluation | 1 | 0.6% |
Public Health Emergency of International Concern | 1 | 0.6% |
Public finance | 1 | 0.6% |
Public health surveillance | 1 | 0.6% |
Purchasing power parity | 1 | 0.6% |
QT interval | 1 | 0.6% |
Qualifications for professional social work | 1 | 0.6% |
Qualitative research | 1 | 0.6% |
Quality assurance | 1 | 0.6% |
Quality of life (healthcare) | 1 | 0.6% |
Quality-adjusted life year | 1 | 0.6% |
RNA-dependent RNA polymerase | 1 | 0.6% |
RTTNEURO | 1 | 0.6% |
Racial segregation in the United States | 1 | 0.6% |
Racing thoughts | 1 | 0.6% |
Racism | 1 | 0.6% |
Rapid antigen test | 1 | 0.6% |
Rational emotive behavior therapy | 1 | 0.6% |
ReCAPTCHA | 1 | 0.6% |
Real-time polymerase chain reaction | 1 | 0.6% |
Recession shapes | 1 | 0.6% |
Record linkage | 1 | 0.6% |
Red Schoendienst | 1 | 0.6% |
Redistribution of income and wealth | 1 | 0.6% |
Regulatory compliance | 1 | 0.6% |
Relative risk | 1 | 0.6% |
Renting | 1 | 0.6% |
Reparations for slavery | 1 | 0.6% |
Research Domain Criteria | 1 | 0.6% |
Respirator | 1 | 0.6% |
Respiratory droplet | 1 | 0.6% |
Retail | 1 | 0.6% |
Revenue | 1 | 0.6% |
Reverse transcription polymerase chain reaction | 1 | 0.6% |
Rio Convention | 1 | 0.6% |
Risk aversion | 1 | 0.6% |
Robust statistics | 1 | 0.6% |
Ron Wyden | 1 | 0.6% |
Safeguarding | 1 | 0.6% |
Safety culture | 1 | 0.6% |
Salary | 1 | 0.6% |
Sales | 1 | 0.6% |
Scatter plot | 1 | 0.6% |
Sea ice | 1 | 0.6% |
Sea level rise | 1 | 0.6% |
Sedative | 1 | 0.6% |
Selection bias | 1 | 0.6% |
Self-medication | 1 | 0.6% |
Sepsis | 1 | 0.6% |
Serious mental illness | 1 | 0.6% |
Seroconversion | 1 | 0.6% |
Serotonin | 1 | 0.6% |
Serotonin–norepinephrine reuptake inhibitor | 1 | 0.6% |
Sex trafficking | 1 | 0.6% |
Sexual and reproductive health | 1 | 0.6% |
Sexual assault | 1 | 0.6% |
Shared decision-making in medicine | 1 | 0.6% |
Sickle cell disease | 1 | 0.6% |
Sinopharm BIBP COVID-19 vaccine | 1 | 0.6% |
Slavery | 1 | 0.6% |
Sleep | 1 | 0.6% |
Sleep disorder | 1 | 0.6% |
Small business | 1 | 0.6% |
Smart city | 1 | 0.6% |
Smoking and pregnancy | 1 | 0.6% |
Smuggling | 1 | 0.6% |
Social Security Disability Insurance | 1 | 0.6% |
Social anxiety disorder | 1 | 0.6% |
Social science | 1 | 0.6% |
Societal racism | 1 | 0.6% |
Spatial analysis | 1 | 0.6% |
Special agent | 1 | 0.6% |
Specific social phobia | 1 | 0.6% |
Sputnik V COVID-19 vaccine | 1 | 0.6% |
Standard deviation | 1 | 0.6% |
Standard error | 1 | 0.6% |
Standard score | 1 | 0.6% |
Startup company | 1 | 0.6% |
Statistical classification | 1 | 0.6% |
Statistical hypothesis testing | 1 | 0.6% |
Stay-at-home order | 1 | 0.6% |
Subprime mortgage crisis | 1 | 0.6% |
Substance abuse prevention | 1 | 0.6% |
Suicidal ideation | 1 | 0.6% |
Superannuation in Australia | 1 | 0.6% |
Supplier-induced demand | 1 | 0.6% |
Support-vector machine | 1 | 0.6% |
Surgery | 1 | 0.6% |
Survey of Income and Program Participation | 1 | 0.6% |
Survival analysis | 1 | 0.6% |
Symptoms of COVID-19 | 1 | 0.6% |
Syncope (medicine) | 1 | 0.6% |
Synthetic cannabinoids | 1 | 0.6% |
System | 1 | 0.6% |
Tapentadol | 1 | 0.6% |
Tardive dyskinesia | 1 | 0.6% |
Taxpayer | 1 | 0.6% |
Teenage pregnancy | 1 | 0.6% |
Telemedicine | 1 | 0.6% |
Telenursing | 1 | 0.6% |
Temperature | 1 | 0.6% |
Tetrahydrocannabinol | 1 | 0.6% |
Thalassemia | 1 | 0.6% |
Tooth decay | 1 | 0.6% |
Trade | 1 | 0.6% |
Tramadol | 1 | 0.6% |
Trans man | 1 | 0.6% |
Trans woman | 1 | 0.6% |
Transcranial direct-current stimulation | 1 | 0.6% |
Transcranial magnetic stimulation | 1 | 0.6% |
Transitional care | 1 | 0.6% |
Travel visa | 1 | 0.6% |
Treaties of the European Union | 1 | 0.6% |
Treatments for PTSD | 1 | 0.6% |
Tropical cyclone | 1 | 0.6% |
Type I and type II errors | 1 | 0.6% |
Underwriting | 1 | 0.6% |
Unemployment | 1 | 0.6% |
Unpaid work | 1 | 0.6% |
Value (economics) | 1 | 0.6% |
Value chain | 1 | 0.6% |
Value-based pricing | 1 | 0.6% |
Varenicline | 1 | 0.6% |
Vikram Patel | 1 | 0.6% |
Virus | 1 | 0.6% |
Voting methods in deliberative assemblies | 1 | 0.6% |
Wealth | 1 | 0.6% |
White British | 1 | 0.6% |
Worry | 1 | 0.6% |
Ziprasidone | 1 | 0.6% |
abs | rel | |
---|---|---|
Activities of daily living | 1 | 100.0% |
Ageing | 1 | 100.0% |
Anesthesia | 1 | 100.0% |
Behavioural sciences | 1 | 100.0% |
Cancer | 1 | 100.0% |
Caregiver | 1 | 100.0% |
Clinical medicine | 1 | 100.0% |
Clinical trial | 1 | 100.0% |
Comorbidity | 1 | 100.0% |
Delirium | 1 | 100.0% |
Dementia | 1 | 100.0% |
Denver Developmental Screening Tests | 1 | 100.0% |
Disability | 1 | 100.0% |
Disease | 1 | 100.0% |
Epidemiology | 1 | 100.0% |
Geriatrics | 1 | 100.0% |
Health | 1 | 100.0% |
Health care | 1 | 100.0% |
Health policy | 1 | 100.0% |
Health sciences | 1 | 100.0% |
Homelessness | 1 | 100.0% |
Major depressive disorder | 1 | 100.0% |
Medical specialties | 1 | 100.0% |
Medicine | 1 | 100.0% |
Mental disorder | 1 | 100.0% |
Mental health | 1 | 100.0% |
Mood disorder | 1 | 100.0% |
Nursing | 1 | 100.0% |
Nursing home care | 1 | 100.0% |
Physical therapy | 1 | 100.0% |
Psychiatry | 1 | 100.0% |
Psychological evaluation | 1 | 100.0% |
Psychology | 1 | 100.0% |
Public health | 1 | 100.0% |
Quality of life | 1 | 100.0% |
Quality-adjusted life year | 1 | 100.0% |
Reliability (statistics) | 1 | 100.0% |
Research | 1 | 100.0% |
Risk | 1 | 100.0% |
Social science | 1 | 100.0% |
Somatic symptom disorder | 1 | 100.0% |
Stress (biology) | 1 | 100.0% |
Surgery | 1 | 100.0% |
Urinary incontinence | 1 | 100.0% |
Validity (statistics) | 1 | 100.0% |
abs | rel | |
---|---|---|
Clinical medicine | 3 | 100.0% |
Health | 3 | 100.0% |
Health care | 3 | 100.0% |
Health sciences | 3 | 100.0% |
Medical specialties | 3 | 100.0% |
Medicine | 3 | 100.0% |
Asplenia | 2 | 66.7% |
Booster dose | 2 | 66.7% |
Childhood immunizations in the United States | 2 | 66.7% |
Chronic condition | 2 | 66.7% |
Chronic obstructive pulmonary disease | 2 | 66.7% |
Contract | 2 | 66.7% |
Employment | 2 | 66.7% |
General medical services | 2 | 66.7% |
General practitioner | 2 | 66.7% |
Haemophilus influenzae | 2 | 66.7% |
Immunization | 2 | 66.7% |
Immunology | 2 | 66.7% |
Parental leave | 2 | 66.7% |
Pension | 2 | 66.7% |
Pneumococcal conjugate vaccine | 2 | 66.7% |
Pneumococcal vaccine | 2 | 66.7% |
Quality and Outcomes Framework | 2 | 66.7% |
Respiratory disease | 2 | 66.7% |
Sick leave | 2 | 66.7% |
Vaccination schedule | 2 | 66.7% |
Vaccine | 2 | 66.7% |
Alcoholism | 1 | 33.3% |
Anxiety disorder | 1 | 33.3% |
Behavioural sciences | 1 | 33.3% |
Bias | 1 | 33.3% |
Blinded experiment | 1 | 33.3% |
Bronchiectasis | 1 | 33.3% |
Clinical psychology | 1 | 33.3% |
Cognitive behavioral therapy | 1 | 33.3% |
Debriefing | 1 | 33.3% |
Depression (mood) | 1 | 33.3% |
Diabetes | 1 | 33.3% |
Disability | 1 | 33.3% |
Diseases and disorders | 1 | 33.3% |
Dose (biochemistry) | 1 | 33.3% |
Human nature | 1 | 33.3% |
Inclusion (education) | 1 | 33.3% |
Influenza | 1 | 33.3% |
Influenza A virus subtype H1N1 | 1 | 33.3% |
Influenza pandemic | 1 | 33.3% |
Intention-to-treat analysis | 1 | 33.3% |
Intervention (counseling) | 1 | 33.3% |
Major depressive disorder | 1 | 33.3% |
Mental disorder | 1 | 33.3% |
Mental health | 1 | 33.3% |
Meta-analysis | 1 | 33.3% |
Pain | 1 | 33.3% |
Percentage | 1 | 33.3% |
Physical therapy | 1 | 33.3% |
Positive psychology | 1 | 33.3% |
Post-traumatic stress disorder | 1 | 33.3% |
Preventive healthcare | 1 | 33.3% |
Psychiatric and mental health nursing | 1 | 33.3% |
Psychiatry | 1 | 33.3% |
Psychiatry-related fields | 1 | 33.3% |
Psychological concepts | 1 | 33.3% |
Psychological trauma | 1 | 33.3% |
Psychology | 1 | 33.3% |
Psychosocial | 1 | 33.3% |
Psychotherapy | 1 | 33.3% |
Public health | 1 | 33.3% |
Quality of life (healthcare) | 1 | 33.3% |
Randomized controlled trial | 1 | 33.3% |
Reporting bias | 1 | 33.3% |
Risk | 1 | 33.3% |
Superannuation in Australia | 1 | 33.3% |
Systematic review | 1 | 33.3% |
Traumatic brain injury | 1 | 33.3% |
abs | rel | |
---|---|---|
Employment | 2 | 100.0% |
Health | 2 | 100.0% |
Health care | 2 | 100.0% |
Asplenia | 1 | 50.0% |
Booster dose | 1 | 50.0% |
Broker | 1 | 50.0% |
Business | 1 | 50.0% |
Childhood immunizations in the United States | 1 | 50.0% |
Chronic condition | 1 | 50.0% |
Chronic obstructive pulmonary disease | 1 | 50.0% |
Clinical medicine | 1 | 50.0% |
Competition | 1 | 50.0% |
Consumer price index | 1 | 50.0% |
Contract | 1 | 50.0% |
Defined benefit pension plan | 1 | 50.0% |
Defined contribution plan | 1 | 50.0% |
Design | 1 | 50.0% |
Diseases and disorders | 1 | 50.0% |
Economy | 1 | 50.0% |
Finance | 1 | 50.0% |
General medical services | 1 | 50.0% |
General practitioner | 1 | 50.0% |
Haemophilus influenzae | 1 | 50.0% |
Health care in the United States | 1 | 50.0% |
Health care reform | 1 | 50.0% |
Health insurance | 1 | 50.0% |
Health insurance coverage in the United States | 1 | 50.0% |
Health insurance marketplace | 1 | 50.0% |
Health sciences | 1 | 50.0% |
Health system | 1 | 50.0% |
Human activities | 1 | 50.0% |
Immunization | 1 | 50.0% |
Immunology | 1 | 50.0% |
Insurance | 1 | 50.0% |
Market (economics) | 1 | 50.0% |
Medical specialties | 1 | 50.0% |
Medicine | 1 | 50.0% |
Parental leave | 1 | 50.0% |
Patient Protection and Affordable Care Act | 1 | 50.0% |
Percentage | 1 | 50.0% |
Perfect competition | 1 | 50.0% |
Pneumococcal conjugate vaccine | 1 | 50.0% |
Pneumococcal vaccine | 1 | 50.0% |
Public health | 1 | 50.0% |
Quality and Outcomes Framework | 1 | 50.0% |
Reinsurance | 1 | 50.0% |
Respiratory disease | 1 | 50.0% |
Retail | 1 | 50.0% |
Risk | 1 | 50.0% |
Sales | 1 | 50.0% |
Service industries | 1 | 50.0% |
Underwriting | 1 | 50.0% |
Vaccination schedule | 1 | 50.0% |
Vaccine | 1 | 50.0% |
Value (economics) | 1 | 50.0% |
abs | rel | |
---|---|---|
Health | 7 | 100.0% |
Medical diagnosis | 5 | 71.4% |
Clinical medicine | 4 | 57.1% |
Health care | 4 | 57.1% |
Medical specialties | 4 | 57.1% |
Medicine | 4 | 57.1% |
Risk | 4 | 57.1% |
Disease | 3 | 42.9% |
Evidence-based medicine | 3 | 42.9% |
Health economics | 3 | 42.9% |
Health insurance | 3 | 42.9% |
Health sciences | 3 | 42.9% |
Human activities | 3 | 42.9% |
Insurance | 3 | 42.9% |
Medicare (United States) | 3 | 42.9% |
Patient Protection and Affordable Care Act | 3 | 42.9% |
Research | 3 | 42.9% |
Sensitivity and specificity | 3 | 42.9% |
Abnormal psychology | 2 | 28.6% |
Agoraphobia | 2 | 28.6% |
Anxiety disorder | 2 | 28.6% |
Avian influenza | 2 | 28.6% |
Basic reproduction number | 2 | 28.6% |
Behavioural sciences | 2 | 28.6% |
Booster dose | 2 | 28.6% |
Clinical psychology | 2 | 28.6% |
Cognitive behavioral therapy | 2 | 28.6% |
Consumer price index | 2 | 28.6% |
Coronavirus disease 2019 | 2 | 28.6% |
Data analysis | 2 | 28.6% |
Disability | 2 | 28.6% |
Disease surveillance | 2 | 28.6% |
Economics of service industries | 2 | 28.6% |
Epidemiology | 2 | 28.6% |
Errors and residuals | 2 | 28.6% |
Health care prices in the United States | 2 | 28.6% |
Herd immunity | 2 | 28.6% |
Infection | 2 | 28.6% |
Influenza | 2 | 28.6% |
Influenza A virus subtype H5N1 | 2 | 28.6% |
Major depressive disorder | 2 | 28.6% |
Medicaid | 2 | 28.6% |
Mental and behavioural disorders | 2 | 28.6% |
Mental health | 2 | 28.6% |
Panic attack | 2 | 28.6% |
Phobia | 2 | 28.6% |
Positive psychology | 2 | 28.6% |
Posttraumatic stress disorder | 2 | 28.6% |
Psychiatric assessment | 2 | 28.6% |
Psychiatric diagnosis | 2 | 28.6% |
Psychiatry | 2 | 28.6% |
Psychiatry-related fields | 2 | 28.6% |
Psychological concepts | 2 | 28.6% |
Psychology | 2 | 28.6% |
Public health | 2 | 28.6% |
Serology | 2 | 28.6% |
The Path to Prosperity | 2 | 28.6% |
Vaccine | 2 | 28.6% |
Absenteeism | 1 | 14.3% |
Actuarial science | 1 | 14.3% |
Alcoholism | 1 | 14.3% |
Antidepressant | 1 | 14.3% |
Antipsychotic | 1 | 14.3% |
Anxiety | 1 | 14.3% |
Anxiety disorders | 1 | 14.3% |
Applied psychology | 1 | 14.3% |
Behaviour therapy | 1 | 14.3% |
Caregiver | 1 | 14.3% |
Chronic condition | 1 | 14.3% |
Cognition | 1 | 14.3% |
Comorbidity | 1 | 14.3% |
Compulsive behavior | 1 | 14.3% |
Depression (mood) | 1 | 14.3% |
Diagnostic and Statistical Manual of Mental Disorders | 1 | 14.3% |
Disability-adjusted life year | 1 | 14.3% |
Diseases and disorders | 1 | 14.3% |
Emotion | 1 | 14.3% |
Emotions | 1 | 14.3% |
Evaluation | 1 | 14.3% |
Eye movement desensitization and reprocessing | 1 | 14.3% |
False positives and false negatives | 1 | 14.3% |
Fee-for-service | 1 | 14.3% |
Finance | 1 | 14.3% |
General practitioner | 1 | 14.3% |
Generalized anxiety disorder | 1 | 14.3% |
Government | 1 | 14.3% |
Grammatical gender | 1 | 14.3% |
Health care in the United States | 1 | 14.3% |
Health care reform | 1 | 14.3% |
Health insurance marketplace | 1 | 14.3% |
Health professional | 1 | 14.3% |
Healthcare in the Netherlands | 1 | 14.3% |
Human diseases and disorders | 1 | 14.3% |
Learning disability | 1 | 14.3% |
Likelihood ratios in diagnostic testing | 1 | 14.3% |
MEDLINE | 1 | 14.3% |
Market (economics) | 1 | 14.3% |
Medical guideline | 1 | 14.3% |
Medical test | 1 | 14.3% |
Medicare Advantage | 1 | 14.3% |
Medigap | 1 | 14.3% |
Mental disorder | 1 | 14.3% |
Meta-analysis | 1 | 14.3% |
Monoamine oxidase inhibitor | 1 | 14.3% |
Neuroscience | 1 | 14.3% |
Neurotic, stress-related and somatoform disorders | 1 | 14.3% |
Obsessive–compulsive disorder | 1 | 14.3% |
PHQ-9 | 1 | 14.3% |
Panic disorder | 1 | 14.3% |
Positive and negative predictive values | 1 | 14.3% |
Poverty | 1 | 14.3% |
Prevalence | 1 | 14.3% |
Primary care | 1 | 14.3% |
Privacy | 1 | 14.3% |
Psychiatric diseases and disorders | 1 | 14.3% |
Psychological trauma | 1 | 14.3% |
Psychopathology | 1 | 14.3% |
Psychotherapy | 1 | 14.3% |
Public policy | 1 | 14.3% |
RTTNEURO | 1 | 14.3% |
Randomized controlled trial | 1 | 14.3% |
Receiver operating characteristic | 1 | 14.3% |
Reinsurance | 1 | 14.3% |
School voucher | 1 | 14.3% |
Selective serotonin reuptake inhibitor | 1 | 14.3% |
Self-insurance | 1 | 14.3% |
Social anxiety disorder | 1 | 14.3% |
Social constructionism | 1 | 14.3% |
Social issues | 1 | 14.3% |
Somatic symptom disorder | 1 | 14.3% |
Specific social phobia | 1 | 14.3% |
Substance abuse | 1 | 14.3% |
Systematic review | 1 | 14.3% |
Therapy | 1 | 14.3% |
Worry | 1 | 14.3% |
abs | rel | |
---|---|---|
Health | 3 | 100.0% |
Health care | 3 | 100.0% |
Evidence-based medicine | 2 | 66.7% |
Major depressive disorder | 2 | 66.7% |
Medicare (United States) | 2 | 66.7% |
Medicine | 2 | 66.7% |
Mental disorder | 2 | 66.7% |
Mental health | 2 | 66.7% |
Psychology | 2 | 66.7% |
Substance abuse | 2 | 66.7% |
Traumatic brain injury | 2 | 66.7% |
Veteran | 2 | 66.7% |
Abuse | 1 | 33.3% |
Affordable Care Act | 1 | 33.3% |
Alcohol abuse | 1 | 33.3% |
Alcoholism | 1 | 33.3% |
Behavioural sciences | 1 | 33.3% |
Clinic | 1 | 33.3% |
Clinical medicine | 1 | 33.3% |
Clinical psychology | 1 | 33.3% |
Cognitive behavioral therapy | 1 | 33.3% |
Combat stress reaction | 1 | 33.3% |
Concussion | 1 | 33.3% |
Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury | 1 | 33.3% |
Diagnostic and Statistical Manual of Mental Disorders | 1 | 33.3% |
Disease | 1 | 33.3% |
Dual diagnosis | 1 | 33.3% |
Economics of service industries | 1 | 33.3% |
Emergency department | 1 | 33.3% |
Eye movement desensitization and reprocessing | 1 | 33.3% |
Federal Employees Health Benefits Program | 1 | 33.3% |
Fee-for-service | 1 | 33.3% |
Government | 1 | 33.3% |
Gynaecology | 1 | 33.3% |
Health economics | 1 | 33.3% |
Health professional | 1 | 33.3% |
Health sciences | 1 | 33.3% |
Health system | 1 | 33.3% |
Healthcare reform in the United States | 1 | 33.3% |
Hospital | 1 | 33.3% |
Human activities | 1 | 33.3% |
Insurance | 1 | 33.3% |
Medical guideline | 1 | 33.3% |
Medical home | 1 | 33.3% |
Medical specialties | 1 | 33.3% |
Osteopathy | 1 | 33.3% |
Patient | 1 | 33.3% |
Patient safety | 1 | 33.3% |
Pay for performance (healthcare) | 1 | 33.3% |
Physical therapy | 1 | 33.3% |
Post-traumatic stress disorder | 1 | 33.3% |
Posttraumatic stress disorder | 1 | 33.3% |
Pregnancy | 1 | 33.3% |
Prenatal care | 1 | 33.3% |
Preterm birth | 1 | 33.3% |
Preventive healthcare | 1 | 33.3% |
Primary care | 1 | 33.3% |
Psychological concepts | 1 | 33.3% |
Psychological trauma | 1 | 33.3% |
Psychotherapy | 1 | 33.3% |
Randomized controlled trial | 1 | 33.3% |
Recovery approach | 1 | 33.3% |
Research | 1 | 33.3% |
Retirement | 1 | 33.3% |
Screening (medicine) | 1 | 33.3% |
Self-medication | 1 | 33.3% |
Social stigma | 1 | 33.3% |
Stress (biology) | 1 | 33.3% |
The Path to Prosperity | 1 | 33.3% |
Therapy | 1 | 33.3% |
Transitional care | 1 | 33.3% |
Treatments for PTSD | 1 | 33.3% |
Women's health | 1 | 33.3% |
abs | rel | |
---|---|---|
Affordable Care Act | 2 | 100.0% |
Employment | 2 | 100.0% |
Health | 2 | 100.0% |
Health care | 2 | 100.0% |
Health economics | 2 | 100.0% |
Health insurance | 2 | 100.0% |
Health insurance in the United States | 2 | 100.0% |
Insurance | 2 | 100.0% |
Medicaid | 2 | 100.0% |
Medicare (United States) | 2 | 100.0% |
Basic needs | 1 | 50.0% |
Census | 1 | 50.0% |
Child care | 1 | 50.0% |
Child support | 1 | 50.0% |
Chronic condition | 1 | 50.0% |
Cost of living | 1 | 50.0% |
Dietary supplement | 1 | 50.0% |
Disproportionate share hospital | 1 | 50.0% |
Economics of service industries | 1 | 50.0% |
Economy | 1 | 50.0% |
Finance | 1 | 50.0% |
Food safety | 1 | 50.0% |
Government | 1 | 50.0% |
Health care prices in the United States | 1 | 50.0% |
Health insurance coverage in the United States | 1 | 50.0% |
Health insurance mandate | 1 | 50.0% |
Health insurance marketplace | 1 | 50.0% |
Health policy | 1 | 50.0% |
Human activities | 1 | 50.0% |
Income | 1 | 50.0% |
Individual retirement account | 1 | 50.0% |
Kathleen Sebelius | 1 | 50.0% |
Medicare Part D | 1 | 50.0% |
Medicine | 1 | 50.0% |
Mental disorder | 1 | 50.0% |
Out-of-pocket expense | 1 | 50.0% |
Patient safety | 1 | 50.0% |
Pension | 1 | 50.0% |
Policy | 1 | 50.0% |
Poverty | 1 | 50.0% |
Poverty in the United States | 1 | 50.0% |
Poverty threshold | 1 | 50.0% |
Pre-existing condition | 1 | 50.0% |
Preventive healthcare | 1 | 50.0% |
Project Bioshield Act | 1 | 50.0% |
Retirement | 1 | 50.0% |
Risk | 1 | 50.0% |
Social Security (United States) | 1 | 50.0% |
Supplemental Nutrition Assistance Program | 1 | 50.0% |
Supplemental Security Income | 1 | 50.0% |
Survey methodology | 1 | 50.0% |
Survey of Income and Program Participation | 1 | 50.0% |
Tax | 1 | 50.0% |
Welfare | 1 | 50.0% |
abs | rel | |
---|---|---|
Health | 4 | 100.0% |
Health care | 3 | 75.0% |
Risk | 3 | 75.0% |
Behavioural sciences | 2 | 50.0% |
Clinical medicine | 2 | 50.0% |
Clinical psychology | 2 | 50.0% |
Cognitive behavioral therapy | 2 | 50.0% |
Disease | 2 | 50.0% |
Government | 2 | 50.0% |
Health insurance | 2 | 50.0% |
Health insurance marketplace | 2 | 50.0% |
Insurance | 2 | 50.0% |
Major depressive disorder | 2 | 50.0% |
Medicaid | 2 | 50.0% |
Medical diagnosis | 2 | 50.0% |
Medical specialties | 2 | 50.0% |
Medicare (United States) | 2 | 50.0% |
Medicine | 2 | 50.0% |
Mental disorder | 2 | 50.0% |
Mental health | 2 | 50.0% |
Neuroscience | 2 | 50.0% |
Patient Protection and Affordable Care Act | 2 | 50.0% |
Poverty in the United States | 2 | 50.0% |
Premium tax credit | 2 | 50.0% |
Psychiatry | 2 | 50.0% |
Psychiatry-related fields | 2 | 50.0% |
Psychology | 2 | 50.0% |
Psychotherapy | 2 | 50.0% |
Reinsurance | 2 | 50.0% |
Tax | 2 | 50.0% |
Tax credit | 2 | 50.0% |
Abnormal psychology | 1 | 25.0% |
Adult | 1 | 25.0% |
Adverse selection | 1 | 25.0% |
Antidepressant | 1 | 25.0% |
Antipsychotic | 1 | 25.0% |
Anxiety | 1 | 25.0% |
Anxiety disorder | 1 | 25.0% |
Bipolar disorder | 1 | 25.0% |
Cancer | 1 | 25.0% |
Cardiovascular disease | 1 | 25.0% |
Caregiver | 1 | 25.0% |
Children's Health Insurance Program | 1 | 25.0% |
Citalopram | 1 | 25.0% |
Community mental health service | 1 | 25.0% |
Comorbidity | 1 | 25.0% |
Corporate social responsibility | 1 | 25.0% |
Depression (mood) | 1 | 25.0% |
Diabetes mellitus | 1 | 25.0% |
Diabetes mellitus type 2 | 1 | 25.0% |
Diagnosis of schizophrenia | 1 | 25.0% |
Diagnostic and Statistical Manual of Mental Disorders | 1 | 25.0% |
Disability | 1 | 25.0% |
Disability-adjusted life year | 1 | 25.0% |
Disease burden | 1 | 25.0% |
Dopamine | 1 | 25.0% |
Dopamine hypothesis of schizophrenia | 1 | 25.0% |
Dyskinesia | 1 | 25.0% |
Dysthymia | 1 | 25.0% |
Early intervention in psychosis | 1 | 25.0% |
Economy | 1 | 25.0% |
Employment | 1 | 25.0% |
Evidence-based medicine | 1 | 25.0% |
Federally Qualified Health Center | 1 | 25.0% |
Financial law | 1 | 25.0% |
Financial risk | 1 | 25.0% |
Fluoxetine | 1 | 25.0% |
General practitioner | 1 | 25.0% |
Haloperidol | 1 | 25.0% |
Health care prices in the United States | 1 | 25.0% |
Health economics | 1 | 25.0% |
Health insurance coverage in the United States | 1 | 25.0% |
Health insurance in the United States | 1 | 25.0% |
Health insurance mandate | 1 | 25.0% |
Health professional | 1 | 25.0% |
Health sciences | 1 | 25.0% |
Hospital | 1 | 25.0% |
Human activities | 1 | 25.0% |
Income | 1 | 25.0% |
Interest | 1 | 25.0% |
Management of depression | 1 | 25.0% |
Management of schizophrenia | 1 | 25.0% |
Mania | 1 | 25.0% |
Market (economics) | 1 | 25.0% |
Medical guideline | 1 | 25.0% |
Mental Health Act 1983 | 1 | 25.0% |
Mental and behavioural disorders | 1 | 25.0% |
Meta-analysis | 1 | 25.0% |
Metabolic syndrome | 1 | 25.0% |
Mirtazapine | 1 | 25.0% |
Moclobemide | 1 | 25.0% |
Mood disorder | 1 | 25.0% |
Obesity | 1 | 25.0% |
Paroxetine | 1 | 25.0% |
Patient | 1 | 25.0% |
Percentage | 1 | 25.0% |
Population health | 1 | 25.0% |
Posttraumatic stress disorder | 1 | 25.0% |
Poverty | 1 | 25.0% |
Primary care | 1 | 25.0% |
Psychiatric diagnosis | 1 | 25.0% |
Psychiatric hospital | 1 | 25.0% |
Psychological concepts | 1 | 25.0% |
Psychosis | 1 | 25.0% |
Psychosocial | 1 | 25.0% |
Public sphere | 1 | 25.0% |
Qualitative research | 1 | 25.0% |
Randomized controlled trial | 1 | 25.0% |
Recovery approach | 1 | 25.0% |
Regulatory Flexibility Act | 1 | 25.0% |
Research | 1 | 25.0% |
Schizophrenia | 1 | 25.0% |
School voucher | 1 | 25.0% |
Selective serotonin reuptake inhibitor | 1 | 25.0% |
Serotonin | 1 | 25.0% |
Sertraline | 1 | 25.0% |
Social Security (United States) | 1 | 25.0% |
Social stigma | 1 | 25.0% |
Subsidy | 1 | 25.0% |
Suicide | 1 | 25.0% |
Systematic review | 1 | 25.0% |
Tardive dyskinesia | 1 | 25.0% |
Taxpayer | 1 | 25.0% |
Tricyclic antidepressant | 1 | 25.0% |
Unfunded mandate | 1 | 25.0% |
United States Consumer Price Index | 1 | 25.0% |
Venlafaxine | 1 | 25.0% |
Ziprasidone | 1 | 25.0% |
abs | rel | |
---|---|---|
Health | 5 | 83.3% |
Health care | 4 | 66.7% |
Human activities | 4 | 66.7% |
Medicaid | 4 | 66.7% |
Medicare (United States) | 4 | 66.7% |
Health economics | 3 | 50.0% |
Health sciences | 3 | 50.0% |
Insurance | 3 | 50.0% |
Risk | 3 | 50.0% |
Childbirth | 2 | 33.3% |
Health insurance | 2 | 33.3% |
Infant | 2 | 33.3% |
Medicine | 2 | 33.3% |
Patient Protection and Affordable Care Act | 2 | 33.3% |
Pregnancy | 2 | 33.3% |
Preterm birth | 2 | 33.3% |
Public health | 2 | 33.3% |
Public services | 2 | 33.3% |
Social programs | 2 | 33.3% |
Substance abuse | 2 | 33.3% |
Adolescence | 1 | 16.7% |
Alcoholic drink | 1 | 16.7% |
Attachment theory | 1 | 16.7% |
Behavioural sciences | 1 | 16.7% |
Best practice | 1 | 16.7% |
Birth control | 1 | 16.7% |
Birth weight | 1 | 16.7% |
Cannabis (drug) | 1 | 16.7% |
Caregiver | 1 | 16.7% |
Children's Health Insurance Program | 1 | 16.7% |
Choice architecture | 1 | 16.7% |
Clinical medicine | 1 | 16.7% |
Clinical supervision | 1 | 16.7% |
Cognition | 1 | 16.7% |
Community mental health service | 1 | 16.7% |
Consent | 1 | 16.7% |
Corporate social responsibility | 1 | 16.7% |
Designer drug | 1 | 16.7% |
Determinants of health | 1 | 16.7% |
Dietitian | 1 | 16.7% |
Diseases and disorders | 1 | 16.7% |
Doctor of Medicine | 1 | 16.7% |
Drugs | 1 | 16.7% |
Drugs acting on the nervous system | 1 | 16.7% |
Economy | 1 | 16.7% |
Education | 1 | 16.7% |
Evaluation | 1 | 16.7% |
Fall prevention | 1 | 16.7% |
Family planning | 1 | 16.7% |
Fee-for-service | 1 | 16.7% |
Foster care | 1 | 16.7% |
Government | 1 | 16.7% |
Grandparent | 1 | 16.7% |
Health Insurance Portability and Accountability Act | 1 | 16.7% |
Health care prices in the United States | 1 | 16.7% |
Health equity | 1 | 16.7% |
Health insurance marketplace | 1 | 16.7% |
Health policy | 1 | 16.7% |
Human reproduction | 1 | 16.7% |
Illegal drug trade | 1 | 16.7% |
Infant mortality | 1 | 16.7% |
Information | 1 | 16.7% |
Licensure | 1 | 16.7% |
Liquor | 1 | 16.7% |
Low birth weight | 1 | 16.7% |
MDMA | 1 | 16.7% |
Managed care | 1 | 16.7% |
Market (economics) | 1 | 16.7% |
Maternal death | 1 | 16.7% |
Medical specialties | 1 | 16.7% |
Medicare Part D | 1 | 16.7% |
Mental disorder | 1 | 16.7% |
Mental health | 1 | 16.7% |
Mortality rate | 1 | 16.7% |
Mother | 1 | 16.7% |
National Provider Identifier | 1 | 16.7% |
Nursing | 1 | 16.7% |
Obesity | 1 | 16.7% |
Office of Inspector General (United States) | 1 | 16.7% |
Option (finance) | 1 | 16.7% |
Parent | 1 | 16.7% |
Parenting | 1 | 16.7% |
Policy | 1 | 16.7% |
Population health | 1 | 16.7% |
Postpartum depression | 1 | 16.7% |
Postpartum period | 1 | 16.7% |
Poverty in the United States | 1 | 16.7% |
Premium tax credit | 1 | 16.7% |
Prenatal care | 1 | 16.7% |
Prenatal development | 1 | 16.7% |
Prohibition | 1 | 16.7% |
Prohibition of drugs | 1 | 16.7% |
Psychoactive drug | 1 | 16.7% |
Psychoactive drugs | 1 | 16.7% |
Psychology | 1 | 16.7% |
Psychosocial | 1 | 16.7% |
Psychotherapy | 1 | 16.7% |
Regulatory Flexibility Act | 1 | 16.7% |
Reinsurance | 1 | 16.7% |
Retirement | 1 | 16.7% |
Risk aversion | 1 | 16.7% |
Services sector of the economy | 1 | 16.7% |
Simulation | 1 | 16.7% |
Social Security (United States) | 1 | 16.7% |
Social aspects of psychoactive drugs | 1 | 16.7% |
Social determinants of health | 1 | 16.7% |
Social work | 1 | 16.7% |
Subsidy | 1 | 16.7% |
Synthetic cannabinoids | 1 | 16.7% |
Tax | 1 | 16.7% |
Tax credit | 1 | 16.7% |
Title X | 1 | 16.7% |
United States Consumer Price Index | 1 | 16.7% |
WIC | 1 | 16.7% |
Welfare | 1 | 16.7% |
abs | rel | |
---|---|---|
Health | 5 | 100.0% |
Health care | 4 | 80.0% |
Risk | 4 | 80.0% |
Abnormal psychology | 3 | 60.0% |
Behavioural sciences | 3 | 60.0% |
Clinical medicine | 3 | 60.0% |
Clinical psychology | 3 | 60.0% |
Disease | 3 | 60.0% |
Health insurance | 3 | 60.0% |
Insurance | 3 | 60.0% |
Medical specialties | 3 | 60.0% |
Medicine | 3 | 60.0% |
Mental health | 3 | 60.0% |
Psychiatry | 3 | 60.0% |
Psychiatry-related fields | 3 | 60.0% |
Psychology | 3 | 60.0% |
Substance abuse | 3 | 60.0% |
Alcoholism | 2 | 40.0% |
Autism | 2 | 40.0% |
Cognitive behavioral therapy | 2 | 40.0% |
Corporate social responsibility | 2 | 40.0% |
Diagnostic and Statistical Manual of Mental Disorders | 2 | 40.0% |
Disability | 2 | 40.0% |
Evidence-based medicine | 2 | 40.0% |
Health economics | 2 | 40.0% |
Health policy | 2 | 40.0% |
Health sciences | 2 | 40.0% |
Major depressive disorder | 2 | 40.0% |
Medicaid | 2 | 40.0% |
Medical diagnosis | 2 | 40.0% |
Medicare (United States) | 2 | 40.0% |
Medication | 2 | 40.0% |
Mental and behavioural disorders | 2 | 40.0% |
Mental disorder | 2 | 40.0% |
Patient | 2 | 40.0% |
Patient Protection and Affordable Care Act | 2 | 40.0% |
Positive psychology | 2 | 40.0% |
Psychological concepts | 2 | 40.0% |
Psychosocial | 2 | 40.0% |
Psychotherapy | 2 | 40.0% |
Substance dependence | 2 | 40.0% |
Substance use disorder | 2 | 40.0% |
Welfare | 2 | 40.0% |
Adolescence | 1 | 20.0% |
Adverse selection | 1 | 20.0% |
Anti-social behaviour | 1 | 20.0% |
Anticonvulsant | 1 | 20.0% |
Antidepressant | 1 | 20.0% |
Antipsychotic | 1 | 20.0% |
Antisocial personality disorder | 1 | 20.0% |
Anxiety | 1 | 20.0% |
Anxiety disorder | 1 | 20.0% |
Applied psychology | 1 | 20.0% |
Asperger syndrome | 1 | 20.0% |
Attention deficit hyperactivity disorder | 1 | 20.0% |
Autism spectrum | 1 | 20.0% |
Best practice | 1 | 20.0% |
Bias | 1 | 20.0% |
Bipolar disorder | 1 | 20.0% |
Blinded experiment | 1 | 20.0% |
Cannabis (drug) | 1 | 20.0% |
Cannabis use disorder | 1 | 20.0% |
Capitation (healthcare) | 1 | 20.0% |
Cardiovascular disease | 1 | 20.0% |
Caregiver | 1 | 20.0% |
Child development | 1 | 20.0% |
Childbirth | 1 | 20.0% |
Childhood psychiatric disorders | 1 | 20.0% |
Chronic condition | 1 | 20.0% |
Clinical trial | 1 | 20.0% |
Cognition | 1 | 20.0% |
Cognitive science | 1 | 20.0% |
Community mental health service | 1 | 20.0% |
Comorbidity | 1 | 20.0% |
Contingency management | 1 | 20.0% |
Contract | 1 | 20.0% |
Copayment | 1 | 20.0% |
Correlation and dependence | 1 | 20.0% |
Cost-effectiveness analysis | 1 | 20.0% |
Creative Commons license | 1 | 20.0% |
Culture | 1 | 20.0% |
DSM-5 | 1 | 20.0% |
Demand | 1 | 20.0% |
Dementia | 1 | 20.0% |
Developmental disabilities | 1 | 20.0% |
Disability-adjusted life year | 1 | 20.0% |
Discrimination | 1 | 20.0% |
Disease burden | 1 | 20.0% |
Disorders of psychological development | 1 | 20.0% |
Economic equilibrium | 1 | 20.0% |
Economics | 1 | 20.0% |
Educational psychology | 1 | 20.0% |
Effect size | 1 | 20.0% |
Elasticity (economics) | 1 | 20.0% |
Electroconvulsive therapy | 1 | 20.0% |
Emergency | 1 | 20.0% |
Employment | 1 | 20.0% |
Epidemiology | 1 | 20.0% |
Epilepsy | 1 | 20.0% |
Epileptic seizure | 1 | 20.0% |
Errors and residuals | 1 | 20.0% |
Essential health benefits | 1 | 20.0% |
Fetal alcohol spectrum disorder | 1 | 20.0% |
Finance | 1 | 20.0% |
Fixed effects model | 1 | 20.0% |
Formulary (pharmacy) | 1 | 20.0% |
Generic drug | 1 | 20.0% |
Global mental health | 1 | 20.0% |
Government | 1 | 20.0% |
HIV/AIDS | 1 | 20.0% |
Headache | 1 | 20.0% |
Health care prices in the United States | 1 | 20.0% |
Health literacy | 1 | 20.0% |
Health professional | 1 | 20.0% |
Health system | 1 | 20.0% |
Hospital | 1 | 20.0% |
Human activities | 1 | 20.0% |
Human development | 1 | 20.0% |
Human nature | 1 | 20.0% |
Incentive | 1 | 20.0% |
Infection | 1 | 20.0% |
Intellectual disability | 1 | 20.0% |
Intelligence quotient | 1 | 20.0% |
Interest | 1 | 20.0% |
Learning disability | 1 | 20.0% |
Linear regression | 1 | 20.0% |
Management of HIV/AIDS | 1 | 20.0% |
Management of depression | 1 | 20.0% |
Market (economics) | 1 | 20.0% |
Medical humanities | 1 | 20.0% |
Medicare Advantage | 1 | 20.0% |
Medicare Part D | 1 | 20.0% |
Meta-analysis | 1 | 20.0% |
Migraine | 1 | 20.0% |
Moral hazard | 1 | 20.0% |
Motivation | 1 | 20.0% |
Nervous system | 1 | 20.0% |
Neurological disorder | 1 | 20.0% |
Neurology | 1 | 20.0% |
Neuroscience | 1 | 20.0% |
Non-communicable disease | 1 | 20.0% |
Opioid use disorder | 1 | 20.0% |
Ordinary least squares | 1 | 20.0% |
Out-of-pocket expense | 1 | 20.0% |
Percentile | 1 | 20.0% |
Pervasive developmental disorder | 1 | 20.0% |
Pervasive developmental disorders | 1 | 20.0% |
Pesticide | 1 | 20.0% |
Pharmacy benefit management | 1 | 20.0% |
Policy | 1 | 20.0% |
Poverty | 1 | 20.0% |
Prediction | 1 | 20.0% |
Premium tax credit | 1 | 20.0% |
Prescription drug | 1 | 20.0% |
Preventive healthcare | 1 | 20.0% |
Price | 1 | 20.0% |
Price elasticity of demand | 1 | 20.0% |
Primary care | 1 | 20.0% |
Primary healthcare | 1 | 20.0% |
Profit (economics) | 1 | 20.0% |
Psychiatric and mental health nursing | 1 | 20.0% |
Psychiatric assessment | 1 | 20.0% |
Psychiatric diagnosis | 1 | 20.0% |
Psychopathology | 1 | 20.0% |
Psychosis | 1 | 20.0% |
Public finance | 1 | 20.0% |
Public health | 1 | 20.0% |
Randomized controlled trial | 1 | 20.0% |
Regression analysis | 1 | 20.0% |
Regulatory Flexibility Act | 1 | 20.0% |
Reinsurance | 1 | 20.0% |
Reporting bias | 1 | 20.0% |
Research | 1 | 20.0% |
Revenue | 1 | 20.0% |
Risk management | 1 | 20.0% |
Schizophrenia | 1 | 20.0% |
Selection bias | 1 | 20.0% |
Selective serotonin reuptake inhibitor | 1 | 20.0% |
Self-care | 1 | 20.0% |
Self-harm | 1 | 20.0% |
Self-insurance | 1 | 20.0% |
Simulation | 1 | 20.0% |
Social constructionism | 1 | 20.0% |
Social stigma | 1 | 20.0% |
Socioeconomic status | 1 | 20.0% |
Standard score | 1 | 20.0% |
Statistics | 1 | 20.0% |
Subsidy | 1 | 20.0% |
Suicide | 1 | 20.0% |
Sustainable Development Goals | 1 | 20.0% |
Systematic review | 1 | 20.0% |
Tax | 1 | 20.0% |
Tax credit | 1 | 20.0% |
Therapy | 1 | 20.0% |
Tricyclic antidepressant | 1 | 20.0% |
United States Consumer Price Index | 1 | 20.0% |
Vikram Patel | 1 | 20.0% |
abs | rel | |
---|---|---|
Health | 11 | 100.0% |
Health care | 11 | 100.0% |
Health insurance | 9 | 81.8% |
Medicare (United States) | 9 | 81.8% |
Medicine | 8 | 72.7% |
Health economics | 7 | 63.6% |
Health policy | 7 | 63.6% |
Insurance | 7 | 63.6% |
Medicaid | 7 | 63.6% |
Service industries | 7 | 63.6% |
Economics of service industries | 6 | 54.5% |
Health insurance coverage in the United States | 5 | 45.5% |
Health insurance marketplace | 5 | 45.5% |
Human activities | 5 | 45.5% |
Government | 4 | 36.4% |
Health care in the United States | 4 | 36.4% |
Health sciences | 4 | 36.4% |
Patient Protection and Affordable Care Act | 4 | 36.4% |
Public policy | 4 | 36.4% |
Tax | 4 | 36.4% |
Accountable care organization | 3 | 27.3% |
Affordable Care Act | 3 | 27.3% |
Health and politics | 3 | 27.3% |
Health care prices in the United States | 3 | 27.3% |
Health insurance in the United States | 3 | 27.3% |
Health insurance mandate | 3 | 27.3% |
Mental health | 3 | 27.3% |
Policy | 3 | 27.3% |
Risk | 3 | 27.3% |
Abuse | 2 | 18.2% |
Actuarial science | 2 | 18.2% |
Care in the Community | 2 | 18.2% |
Clinical medicine | 2 | 18.2% |
Copayment | 2 | 18.2% |
Data analysis | 2 | 18.2% |
David Shulkin | 2 | 18.2% |
Depression (mood) | 2 | 18.2% |
Economy | 2 | 18.2% |
Finance | 2 | 18.2% |
Hospital | 2 | 18.2% |
Kidney transplantation | 2 | 18.2% |
Liver transplantation | 2 | 18.2% |
Market (economics) | 2 | 18.2% |
Medical diagnosis | 2 | 18.2% |
Medical specialties | 2 | 18.2% |
Medicare Advantage | 2 | 18.2% |
Medicare Part D | 2 | 18.2% |
Military sexual trauma | 2 | 18.2% |
Organ donation | 2 | 18.2% |
Organ transplantation | 2 | 18.2% |
Patient | 2 | 18.2% |
Pay for performance (healthcare) | 2 | 18.2% |
Privacy | 2 | 18.2% |
Psychological trauma | 2 | 18.2% |
Public hospital | 2 | 18.2% |
Public sphere | 2 | 18.2% |
Reconciliation (United States Congress) | 2 | 18.2% |
Reinsurance | 2 | 18.2% |
Residency (medicine) | 2 | 18.2% |
Self-harm | 2 | 18.2% |
Suicide | 2 | 18.2% |
Telehealth | 2 | 18.2% |
Veteran | 2 | 18.2% |
Veterans' Access to Care through Choice, Accountability, and Transparency Act of 2014 | 2 | 18.2% |
Violence | 2 | 18.2% |
Acne | 1 | 9.1% |
Adapalene | 1 | 9.1% |
Adverse selection | 1 | 9.1% |
Behavioural sciences | 1 | 9.1% |
Benzoyl peroxide/clindamycin | 1 | 9.1% |
Breastfeeding | 1 | 9.1% |
Business | 1 | 9.1% |
Charity care | 1 | 9.1% |
Childbirth | 1 | 9.1% |
Childhood | 1 | 9.1% |
Children's Health Insurance Program | 1 | 9.1% |
Coefficient of determination | 1 | 9.1% |
Credit | 1 | 9.1% |
Current Procedural Terminology | 1 | 9.1% |
Deductible | 1 | 9.1% |
Diabetes mellitus | 1 | 9.1% |
Diseases and disorders | 1 | 9.1% |
Drugs | 1 | 9.1% |
Employment | 1 | 9.1% |
Empowering Patients First Act | 1 | 9.1% |
Financial law | 1 | 9.1% |
Financial risk | 1 | 9.1% |
Financial services | 1 | 9.1% |
Health care industry | 1 | 9.1% |
Healthcare | 1 | 9.1% |
Hospital readmission | 1 | 9.1% |
Human development | 1 | 9.1% |
Human reproduction | 1 | 9.1% |
Infant | 1 | 9.1% |
Infant mortality | 1 | 9.1% |
Insurance policy | 1 | 9.1% |
Internship (medicine) | 1 | 9.1% |
Liability insurance | 1 | 9.1% |
Licensed professional counselor | 1 | 9.1% |
Managed care | 1 | 9.1% |
Medical humanities | 1 | 9.1% |
Medical treatments | 1 | 9.1% |
Mother | 1 | 9.1% |
Motherhood | 1 | 9.1% |
Neonatal withdrawal | 1 | 9.1% |
Pharmaceutical sciences | 1 | 9.1% |
Pharmacology | 1 | 9.1% |
Pharmacy | 1 | 9.1% |
Politics | 1 | 9.1% |
Pre-existing condition | 1 | 9.1% |
Prediction | 1 | 9.1% |
Pregnancy | 1 | 9.1% |
Premium tax credit | 1 | 9.1% |
Prenatal development | 1 | 9.1% |
Prescription drug | 1 | 9.1% |
Preterm birth | 1 | 9.1% |
Price | 1 | 9.1% |
Pricing | 1 | 9.1% |
Profit (economics) | 1 | 9.1% |
Public health | 1 | 9.1% |
Simulation | 1 | 9.1% |
Small business | 1 | 9.1% |
Smoking and pregnancy | 1 | 9.1% |
Subsidy | 1 | 9.1% |
Substance abuse | 1 | 9.1% |
Substance dependence | 1 | 9.1% |
Tax credit | 1 | 9.1% |
Welfare | 1 | 9.1% |
abs | rel | |
---|---|---|
Health | 15 | 78.9% |
Health care | 11 | 57.9% |
Health sciences | 9 | 47.4% |
Medicine | 9 | 47.4% |
Risk | 9 | 47.4% |
Health insurance | 8 | 42.1% |
Insurance | 8 | 42.1% |
Opioid | 8 | 42.1% |
Patient Protection and Affordable Care Act | 8 | 42.1% |
Actuarial science | 7 | 36.8% |
Business | 7 | 36.8% |
Capitation (healthcare) | 7 | 36.8% |
Clinical medicine | 7 | 36.8% |
Drug overdose | 7 | 36.8% |
Heroin | 7 | 36.8% |
Medical specialties | 7 | 36.8% |
Prescription drug | 7 | 36.8% |
Reinsurance | 7 | 36.8% |
Tax | 7 | 36.8% |
Buprenorphine | 6 | 31.6% |
Drug development | 6 | 31.6% |
Fee | 6 | 31.6% |
Health policy | 6 | 31.6% |
Naloxone | 6 | 31.6% |
Opioid use disorder | 6 | 31.6% |
Pricing | 6 | 31.6% |
Rebate (marketing) | 6 | 31.6% |
Substance use disorder | 6 | 31.6% |
Trade secret | 6 | 31.6% |
Disease | 5 | 26.3% |
Fentanyl | 5 | 26.3% |
Financial law | 5 | 26.3% |
Financial risk | 5 | 26.3% |
Pharmacy | 5 | 26.3% |
Pro rata | 5 | 26.3% |
Service industries | 5 | 26.3% |
Substance abuse | 5 | 26.3% |
Substance dependence | 5 | 26.3% |
Contract | 4 | 21.1% |
Electronic health record | 4 | 21.1% |
Evidence-based medicine | 4 | 21.1% |
Financial services | 4 | 21.1% |
Health economics | 4 | 21.1% |
Hospital | 4 | 21.1% |
Human activities | 4 | 21.1% |
Market (economics) | 4 | 21.1% |
Medical prescription | 4 | 21.1% |
Medication | 4 | 21.1% |
Opioid epidemic in the United States | 4 | 21.1% |
Pain management | 4 | 21.1% |
Physician | 4 | 21.1% |
Psychoactive drugs | 4 | 21.1% |
Public health | 4 | 21.1% |
Weighted arithmetic mean | 4 | 21.1% |
21st Century Cures Act | 3 | 15.8% |
Analgesic | 3 | 15.8% |
Confidentiality | 3 | 15.8% |
Cost | 3 | 15.8% |
Drugs | 3 | 15.8% |
Health Insurance Portability and Accountability Act | 3 | 15.8% |
Medicare (United States) | 3 | 15.8% |
Nurse practitioner | 3 | 15.8% |
Opioid epidemic | 3 | 15.8% |
Opioid overdose | 3 | 15.8% |
Prescription monitoring program | 3 | 15.8% |
Right to know | 3 | 15.8% |
Social aspects of psychoactive drugs | 3 | 15.8% |
Actuary | 2 | 10.5% |
Adverse selection | 2 | 10.5% |
Behavioural sciences | 2 | 10.5% |
Carfentanil | 2 | 10.5% |
Childbirth | 2 | 10.5% |
Counterfeit consumer goods | 2 | 10.5% |
Drug rehabilitation | 2 | 10.5% |
Emergency department | 2 | 10.5% |
Government | 2 | 10.5% |
Health insurance coverage in the United States | 2 | 10.5% |
Hepatitis | 2 | 10.5% |
Illegal drug trade | 2 | 10.5% |
Income tax in the United States | 2 | 10.5% |
Infant | 2 | 10.5% |
Loss ratio | 2 | 10.5% |
Mental disorder | 2 | 10.5% |
Methadone | 2 | 10.5% |
Office of Inspector General (United States) | 2 | 10.5% |
Organized crime | 2 | 10.5% |
Physical examination | 2 | 10.5% |
Police dog | 2 | 10.5% |
Pregnancy | 2 | 10.5% |
Prenatal development | 2 | 10.5% |
Preventive healthcare | 2 | 10.5% |
Psychiatry | 2 | 10.5% |
Screening (medicine) | 2 | 10.5% |
United States Senate Homeland Security Permanent Subcommittee on Investigations | 2 | 10.5% |
Utilization management | 2 | 10.5% |
Worksheet | 2 | 10.5% |
Addiction | 1 | 5.3% |
Applied psychology | 1 | 5.3% |
Artificial intelligence | 1 | 5.3% |
Audit | 1 | 5.3% |
Average | 1 | 5.3% |
Benzodiazepine | 1 | 5.3% |
Bill (law) | 1 | 5.3% |
Birth defect | 1 | 5.3% |
Breastfeeding | 1 | 5.3% |
Caregiver | 1 | 5.3% |
Chatbot | 1 | 5.3% |
Cleft lip and cleft palate | 1 | 5.3% |
Clinical psychology | 1 | 5.3% |
Cognition | 1 | 5.3% |
Committee | 1 | 5.3% |
Competition | 1 | 5.3% |
Competition (economics) | 1 | 5.3% |
Computer security | 1 | 5.3% |
Copayment | 1 | 5.3% |
Copyright | 1 | 5.3% |
Customs | 1 | 5.3% |
Demand | 1 | 5.3% |
Dental hygienist | 1 | 5.3% |
Dental therapist | 1 | 5.3% |
Dentist | 1 | 5.3% |
Dentistry | 1 | 5.3% |
Diseases and disorders | 1 | 5.3% |
Dose (biochemistry) | 1 | 5.3% |
Drug withdrawal | 1 | 5.3% |
Dual diagnosis | 1 | 5.3% |
Economic growth | 1 | 5.3% |
Economics | 1 | 5.3% |
Economics of service industries | 1 | 5.3% |
Economy | 1 | 5.3% |
Employee benefits | 1 | 5.3% |
Employment | 1 | 5.3% |
Fee-for-service | 1 | 5.3% |
Fetus | 1 | 5.3% |
Finance | 1 | 5.3% |
Gabapentin | 1 | 5.3% |
Group insurance | 1 | 5.3% |
Health care in the United States | 1 | 5.3% |
Health care industry | 1 | 5.3% |
Health care prices in the United States | 1 | 5.3% |
Health equity | 1 | 5.3% |
Health insurance mandate | 1 | 5.3% |
Health insurance marketplace | 1 | 5.3% |
Health professional | 1 | 5.3% |
Home care in the United States | 1 | 5.3% |
Hygiene | 1 | 5.3% |
1 | 5.3% | |
Medicaid | 1 | 5.3% |
Medical cannabis | 1 | 5.3% |
Medical diagnosis | 1 | 5.3% |
Medical guideline | 1 | 5.3% |
Medical humanities | 1 | 5.3% |
Mental and behavioural disorders | 1 | 5.3% |
Mental health | 1 | 5.3% |
Midwife | 1 | 5.3% |
Motion (parliamentary procedure) | 1 | 5.3% |
NHS foundation trust | 1 | 5.3% |
Neonatal intensive care unit | 1 | 5.3% |
Neonatal withdrawal | 1 | 5.3% |
Neonatology | 1 | 5.3% |
Newborn screening | 1 | 5.3% |
Occupational therapy | 1 | 5.3% |
Opiate | 1 | 5.3% |
Opioid withdrawal | 1 | 5.3% |
Opium | 1 | 5.3% |
Patient | 1 | 5.3% |
Pharmacology | 1 | 5.3% |
Physical therapy | 1 | 5.3% |
Physician assistant | 1 | 5.3% |
Poverty | 1 | 5.3% |
Pre-existing condition | 1 | 5.3% |
Prenatal care | 1 | 5.3% |
Price | 1 | 5.3% |
Privacy | 1 | 5.3% |
Provinces and territories of Canada | 1 | 5.3% |
Psychiatric hospital | 1 | 5.3% |
Psychiatry-related fields | 1 | 5.3% |
Psychology | 1 | 5.3% |
Psychosocial | 1 | 5.3% |
Psychotherapy | 1 | 5.3% |
Quality assurance | 1 | 5.3% |
Recovery approach | 1 | 5.3% |
Recovery model | 1 | 5.3% |
Red Schoendienst | 1 | 5.3% |
Retirement | 1 | 5.3% |
Risk management | 1 | 5.3% |
Safeguarding | 1 | 5.3% |
Salary | 1 | 5.3% |
Sickle cell disease | 1 | 5.3% |
Single-payer healthcare | 1 | 5.3% |
Smuggling | 1 | 5.3% |
Special agent | 1 | 5.3% |
Subsidy | 1 | 5.3% |
Supplemental Nutrition Assistance Program | 1 | 5.3% |
Supplier-induced demand | 1 | 5.3% |
Thalassemia | 1 | 5.3% |
Therapy | 1 | 5.3% |
Tooth decay | 1 | 5.3% |
Universal health care | 1 | 5.3% |
Venlafaxine | 1 | 5.3% |
Voting methods in deliberative assemblies | 1 | 5.3% |
Welfare | 1 | 5.3% |
abs | rel | |
---|---|---|
Health | 28 | 96.6% |
Health care | 28 | 96.6% |
Medicine | 28 | 96.6% |
Disease | 25 | 86.2% |
Risk | 23 | 79.3% |
Human activities | 22 | 75.9% |
Research | 22 | 75.9% |
Education | 20 | 69.0% |
Infection | 20 | 69.0% |
Antimicrobial resistance | 19 | 65.5% |
Digital transformation | 19 | 65.5% |
Economic growth | 19 | 65.5% |
Economy | 19 | 65.5% |
Gender | 19 | 65.5% |
Health system | 19 | 65.5% |
Innovation | 19 | 65.5% |
Public health | 19 | 65.5% |
Science | 19 | 65.5% |
Society | 19 | 65.5% |
Strategic planning | 19 | 65.5% |
Sustainability | 19 | 65.5% |
Sustainable Development Goals | 19 | 65.5% |
Technology | 19 | 65.5% |
Ageing | 18 | 62.1% |
Climate change mitigation | 18 | 62.1% |
Cloud computing | 18 | 62.1% |
Competition (economics) | 18 | 62.1% |
Entrepreneurship | 18 | 62.1% |
Evaluation | 18 | 62.1% |
Expert | 18 | 62.1% |
Globalization | 18 | 62.1% |
Infrastructure | 18 | 62.1% |
Market (economics) | 18 | 62.1% |
Open science | 18 | 62.1% |
Preventive healthcare | 18 | 62.1% |
Quality of life | 18 | 62.1% |
Sustainable Development Goal 3 | 18 | 62.1% |
Sustainable Development Goal 9 | 18 | 62.1% |
Artificial intelligence | 17 | 58.6% |
Circular economy | 17 | 58.6% |
Climate resilience | 17 | 58.6% |
Computer security | 17 | 58.6% |
Cultural heritage | 17 | 58.6% |
Democracy | 17 | 58.6% |
Economic inequality | 17 | 58.6% |
Emerging technologies | 17 | 58.6% |
Governance | 17 | 58.6% |
Health promotion | 17 | 58.6% |
Immigration | 17 | 58.6% |
Interoperability | 17 | 58.6% |
Manufacturing | 17 | 58.6% |
Multiculturalism | 17 | 58.6% |
Non-communicable disease | 17 | 58.6% |
Personalized medicine | 17 | 58.6% |
Productivity | 17 | 58.6% |
Security | 17 | 58.6% |
Social exclusion | 17 | 58.6% |
Sustainable development | 17 | 58.6% |
Cyberattack | 16 | 55.2% |
Digital Single Market | 16 | 55.2% |
Health technology | 16 | 55.2% |
Internet of things | 16 | 55.2% |
Sustainable Development Goal 4 | 16 | 55.2% |
Sustainable Development Goal 5 | 16 | 55.2% |
Sustainable Development Goal 8 | 16 | 55.2% |
Vaccine | 16 | 55.2% |
Disability | 15 | 51.7% |
Human migration | 15 | 51.7% |
Automation | 14 | 48.3% |
Big data | 14 | 48.3% |
Child | 14 | 48.3% |
Climate change | 14 | 48.3% |
Computing | 14 | 48.3% |
Epidemiology | 14 | 48.3% |
Health informatics | 14 | 48.3% |
Resource | 14 | 48.3% |
Robotics | 14 | 48.3% |
Treaty on the Functioning of the European Union | 14 | 48.3% |
Culture | 13 | 44.8% |
Privacy | 13 | 44.8% |
Empowerment | 12 | 41.4% |
Health equity | 12 | 41.4% |
Human trafficking | 11 | 37.9% |
Computer network | 10 | 34.5% |
Digital health | 10 | 34.5% |
European Union legislative procedure | 10 | 34.5% |
Gender equality | 10 | 34.5% |
Politics | 10 | 34.5% |
Sustainable Development Goal 12 | 10 | 34.5% |
Welfare | 9 | 31.0% |
Chronic condition | 8 | 27.6% |
Internet | 8 | 27.6% |
Accessibility | 7 | 24.1% |
Low-carbon economy | 7 | 24.1% |
Risk assessment | 7 | 24.1% |
Crisis | 6 | 20.7% |
Europe | 6 | 20.7% |
Health sciences | 6 | 20.7% |
Information privacy | 6 | 20.7% |
Life expectancy | 6 | 20.7% |
Materials science | 6 | 20.7% |
Radicalization | 6 | 20.7% |
Social mobility | 6 | 20.7% |
Social work | 6 | 20.7% |
Cancer | 5 | 17.2% |
Copernicus Programme | 5 | 17.2% |
Medicaid | 5 | 17.2% |
Medical specialties | 5 | 17.2% |
Medication | 5 | 17.2% |
Mental health | 5 | 17.2% |
Natural environment | 5 | 17.2% |
Pollution | 5 | 17.2% |
Synergy | 5 | 17.2% |
Health insurance | 4 | 13.8% |
Life-cycle assessment | 4 | 13.8% |
Medicare (United States) | 4 | 13.8% |
Nanoelectronics | 4 | 13.8% |
Psychotherapy | 4 | 13.8% |
Software | 4 | 13.8% |
Clinical medicine | 3 | 10.3% |
Clinical trial | 3 | 10.3% |
Creative industries | 3 | 10.3% |
Cyber-physical system | 3 | 10.3% |
Cybercrime | 3 | 10.3% |
Employment | 3 | 10.3% |
Evidence-based medicine | 3 | 10.3% |
Health data | 3 | 10.3% |
Health professional | 3 | 10.3% |
Major depressive disorder | 3 | 10.3% |
Mental disorder | 3 | 10.3% |
Pharmacy | 3 | 10.3% |
Prescription drug | 3 | 10.3% |
Psychiatry | 3 | 10.3% |
Randomized controlled trial | 3 | 10.3% |
Research and development | 3 | 10.3% |
Systematic review | 3 | 10.3% |
Telehealth | 3 | 10.3% |
Veteran | 3 | 10.3% |
Adherence (medicine) | 2 | 6.9% |
Adolescence | 2 | 6.9% |
Antipsychotic | 2 | 6.9% |
Behavior | 2 | 6.9% |
Behaviour therapy | 2 | 6.9% |
Behavioural sciences | 2 | 6.9% |
Bias | 2 | 6.9% |
Biosimilar | 2 | 6.9% |
Bipolar disorder | 2 | 6.9% |
Blinded experiment | 2 | 6.9% |
Budget of the European Union | 2 | 6.9% |
Caregiver | 2 | 6.9% |
Clinical psychology | 2 | 6.9% |
Cognitive behavioral therapy | 2 | 6.9% |
Collaboration | 2 | 6.9% |
Competition | 2 | 6.9% |
Confidence interval | 2 | 6.9% |
Crisis management | 2 | 6.9% |
Data analysis | 2 | 6.9% |
Development aid | 2 | 6.9% |
Digital twin | 2 | 6.9% |
Economic development | 2 | 6.9% |
Epidemic | 2 | 6.9% |
Generic drug | 2 | 6.9% |
Government | 2 | 6.9% |
Hazard | 2 | 6.9% |
Health insurance coverage in the United States | 2 | 6.9% |
Individual and political action on climate change | 2 | 6.9% |
Maternal death | 2 | 6.9% |
Medicare Part D | 2 | 6.9% |
Meta-analysis | 2 | 6.9% |
Multistakeholder governance | 2 | 6.9% |
Nancy Pelosi | 2 | 6.9% |
Neuromorphic engineering | 2 | 6.9% |
Non-governmental organization | 2 | 6.9% |
Open access | 2 | 6.9% |
Opioid epidemic in the United States | 2 | 6.9% |
Organization | 2 | 6.9% |
Out-of-pocket expense | 2 | 6.9% |
Participatory design | 2 | 6.9% |
Pharmaceutical industry | 2 | 6.9% |
Photonics | 2 | 6.9% |
Physical therapy | 2 | 6.9% |
Pledge of Allegiance | 2 | 6.9% |
Policy | 2 | 6.9% |
Procurement | 2 | 6.9% |
Progress | 2 | 6.9% |
Psychiatry-related fields | 2 | 6.9% |
Psychological concepts | 2 | 6.9% |
Psychology | 2 | 6.9% |
Psychosocial | 2 | 6.9% |
Public sphere | 2 | 6.9% |
Recruitment | 2 | 6.9% |
Simulation | 2 | 6.9% |
Social innovation | 2 | 6.9% |
Specialty drugs in the United States | 2 | 6.9% |
Strategy | 2 | 6.9% |
Stressor | 2 | 6.9% |
Substance use disorder | 2 | 6.9% |
Suicide | 2 | 6.9% |
Sustainable Development Goal 13 | 2 | 6.9% |
Sustainable Development Goal 16 | 2 | 6.9% |
Sustainable Development Goal 7 | 2 | 6.9% |
Sustainable energy | 2 | 6.9% |
Therapy | 2 | 6.9% |
Traumatic brain injury | 2 | 6.9% |
Abuse | 1 | 3.4% |
Active surveillance of prostate cancer | 1 | 3.4% |
Advanced practice nurse | 1 | 3.4% |
Adverse effect | 1 | 3.4% |
Alcoholism | 1 | 3.4% |
Assertive community treatment | 1 | 3.4% |
Biodiversity | 1 | 3.4% |
Biomarker | 1 | 3.4% |
Borderline personality disorder | 1 | 3.4% |
Buprenorphine | 1 | 3.4% |
Cannabis | 1 | 3.4% |
Carbon neutrality | 1 | 3.4% |
Care in the Community | 1 | 3.4% |
Case management (mental health) | 1 | 3.4% |
Childbirth | 1 | 3.4% |
Climate change adaptation | 1 | 3.4% |
Clozapine | 1 | 3.4% |
Codeine | 1 | 3.4% |
Competition (companies) | 1 | 3.4% |
Confidentiality | 1 | 3.4% |
Confounding | 1 | 3.4% |
Contract | 1 | 3.4% |
Copayment | 1 | 3.4% |
Coronavirus disease 2019 | 1 | 3.4% |
Corporate social responsibility | 1 | 3.4% |
Creativity | 1 | 3.4% |
Critical thinking | 1 | 3.4% |
Cyber-security regulation | 1 | 3.4% |
Depression (mood) | 1 | 3.4% |
Dialectical behavior therapy | 1 | 3.4% |
Digitization | 1 | 3.4% |
Disease burden | 1 | 3.4% |
Drug | 1 | 3.4% |
Drug development | 1 | 3.4% |
Drug rehabilitation | 1 | 3.4% |
Dual diagnosis | 1 | 3.4% |
Ebola | 1 | 3.4% |
Economics | 1 | 3.4% |
Economics of service industries | 1 | 3.4% |
Effect size | 1 | 3.4% |
Efficient energy use | 1 | 3.4% |
Electronic health record | 1 | 3.4% |
Emergency management | 1 | 3.4% |
Engineering | 1 | 3.4% |
Epilepsy | 1 | 3.4% |
Executive Order 12866 | 1 | 3.4% |
Food | 1 | 3.4% |
Global health | 1 | 3.4% |
Greenhouse gas | 1 | 3.4% |
Health care in the United States | 1 | 3.4% |
Health care industry | 1 | 3.4% |
Health economics | 1 | 3.4% |
Health literacy | 1 | 3.4% |
Health policy | 1 | 3.4% |
Health technology in the United States | 1 | 3.4% |
Healthcare industry | 1 | 3.4% |
Horsepower | 1 | 3.4% |
Hospital | 1 | 3.4% |
Human nature | 1 | 3.4% |
Human reproduction | 1 | 3.4% |
Imputation (statistics) | 1 | 3.4% |
Income | 1 | 3.4% |
Industry | 1 | 3.4% |
Institutional review board | 1 | 3.4% |
Insurance | 1 | 3.4% |
Ketamine | 1 | 3.4% |
Kidney transplantation | 1 | 3.4% |
Licensure | 1 | 3.4% |
Lithium (medication) | 1 | 3.4% |
Liver transplantation | 1 | 3.4% |
Managed care | 1 | 3.4% |
Maternal health | 1 | 3.4% |
Medical diagnosis | 1 | 3.4% |
Medical guideline | 1 | 3.4% |
Medical humanities | 1 | 3.4% |
Medical prescription | 1 | 3.4% |
Medical research | 1 | 3.4% |
Mental health professional | 1 | 3.4% |
Mood disorder | 1 | 3.4% |
Motherhood | 1 | 3.4% |
Motivational interviewing | 1 | 3.4% |
National Council Licensure Examination | 1 | 3.4% |
Nature-based solutions | 1 | 3.4% |
Nursing | 1 | 3.4% |
Obesity | 1 | 3.4% |
Odds ratio | 1 | 3.4% |
Open innovation | 1 | 3.4% |
Opioid | 1 | 3.4% |
Opioid use disorder | 1 | 3.4% |
Organ donation | 1 | 3.4% |
Organ transplantation | 1 | 3.4% |
Outcomes research | 1 | 3.4% |
P-value | 1 | 3.4% |
PHQ-9 | 1 | 3.4% |
Paris Agreement | 1 | 3.4% |
Patient Protection and Affordable Care Act | 1 | 3.4% |
Patient participation | 1 | 3.4% |
Patient safety | 1 | 3.4% |
Personal protective equipment | 1 | 3.4% |
Physician | 1 | 3.4% |
Planetary boundaries | 1 | 3.4% |
Positive psychology | 1 | 3.4% |
Post-traumatic stress disorder | 1 | 3.4% |
Posttraumatic stress disorder | 1 | 3.4% |
Powered air-purifying respirator | 1 | 3.4% |
Precision medicine | 1 | 3.4% |
Premium tax credit | 1 | 3.4% |
Prescription drug prices in the United States | 1 | 3.4% |
Prescription monitoring program | 1 | 3.4% |
Primary care | 1 | 3.4% |
Prostate cancer | 1 | 3.4% |
Psychiatric and mental health nursing | 1 | 3.4% |
Psychological resilience | 1 | 3.4% |
Psychological trauma | 1 | 3.4% |
Psychopathology | 1 | 3.4% |
Psychosis | 1 | 3.4% |
Registered nurse | 1 | 3.4% |
Regulatory Flexibility Act | 1 | 3.4% |
Relative risk | 1 | 3.4% |
Reporting bias | 1 | 3.4% |
Research Domain Criteria | 1 | 3.4% |
Residency (medicine) | 1 | 3.4% |
Respirator | 1 | 3.4% |
Respiratory droplet | 1 | 3.4% |
Rio Convention | 1 | 3.4% |
Risk management | 1 | 3.4% |
Schizophrenia | 1 | 3.4% |
Screening (medicine) | 1 | 3.4% |
Selective serotonin reuptake inhibitor | 1 | 3.4% |
Sertraline | 1 | 3.4% |
Severe acute respiratory syndrome | 1 | 3.4% |
Sexual assault | 1 | 3.4% |
Shared decision-making in medicine | 1 | 3.4% |
Social Security (United States) | 1 | 3.4% |
Standard deviation | 1 | 3.4% |
Standard error | 1 | 3.4% |
Statistics | 1 | 3.4% |
Substance abuse | 1 | 3.4% |
Suicidal ideation | 1 | 3.4% |
Suicide prevention | 1 | 3.4% |
System | 1 | 3.4% |
Tax | 1 | 3.4% |
Telemedicine | 1 | 3.4% |
Telenursing | 1 | 3.4% |
Tetrahydrocannabinol | 1 | 3.4% |
Transmission (medicine) | 1 | 3.4% |
Value chain | 1 | 3.4% |
Violence | 1 | 3.4% |
abs | rel | |
---|---|---|
Health | 31 | 96.9% |
Medicine | 27 | 84.4% |
Health care | 24 | 75.0% |
Health sciences | 24 | 75.0% |
Medical specialties | 20 | 62.5% |
Public health | 19 | 59.4% |
Clinical medicine | 17 | 53.1% |
Disease | 15 | 46.9% |
Preventive healthcare | 14 | 43.8% |
Infection | 12 | 37.5% |
Human activities | 11 | 34.4% |
Influenza | 11 | 34.4% |
Coronavirus disease 2019 | 10 | 31.2% |
Health system | 10 | 31.2% |
Risk | 10 | 31.2% |
COVID-19 pandemic | 9 | 28.1% |
Health economics | 9 | 28.1% |
Health policy | 9 | 28.1% |
Maternal health | 9 | 28.1% |
Medicaid | 9 | 28.1% |
Medicare (United States) | 9 | 28.1% |
Epidemiology | 8 | 25.0% |
Medication | 8 | 25.0% |
Opioid | 8 | 25.0% |
Telehealth | 8 | 25.0% |
Chronic condition | 7 | 21.9% |
Health equity | 7 | 21.9% |
Opioid use disorder | 7 | 21.9% |
Prescription drug | 7 | 21.9% |
Drug overdose | 6 | 18.8% |
Economy | 6 | 18.8% |
HIV/AIDS | 6 | 18.8% |
Health care prices in the United States | 6 | 18.8% |
Hospital | 6 | 18.8% |
Maternal death | 6 | 18.8% |
Patient | 6 | 18.8% |
Pay for performance (healthcare) | 6 | 18.8% |
Substance use disorder | 6 | 18.8% |
Economic growth | 5 | 15.6% |
Education | 5 | 15.6% |
Employment | 5 | 15.6% |
Influenza vaccine | 5 | 15.6% |
Kidney transplantation | 5 | 15.6% |
Naloxone | 5 | 15.6% |
Opioid epidemic in the United States | 5 | 15.6% |
Opioid overdose | 5 | 15.6% |
Pandemic | 5 | 15.6% |
Research | 5 | 15.6% |
Social distancing | 5 | 15.6% |
Substance abuse | 5 | 15.6% |
Temporary Assistance for Needy Families | 5 | 15.6% |
Vaccine | 5 | 15.6% |
Ageing | 4 | 12.5% |
Antimicrobial resistance | 4 | 12.5% |
Buprenorphine | 4 | 12.5% |
Cancer | 4 | 12.5% |
Cloud computing | 4 | 12.5% |
Drugs | 4 | 12.5% |
Electronic health record | 4 | 12.5% |
Epidemic | 4 | 12.5% |
European Union legislative procedure | 4 | 12.5% |
Evaluation | 4 | 12.5% |
Evidence-based medicine | 4 | 12.5% |
Health insurance | 4 | 12.5% |
Influenza pandemic | 4 | 12.5% |
Infrastructure | 4 | 12.5% |
Innovation | 4 | 12.5% |
Insurance | 4 | 12.5% |
Mental disorder | 4 | 12.5% |
Mental health | 4 | 12.5% |
Open science | 4 | 12.5% |
Organ transplantation | 4 | 12.5% |
Science | 4 | 12.5% |
Sustainability | 4 | 12.5% |
Sustainable Development Goals | 4 | 12.5% |
Therapy | 4 | 12.5% |
Affordable Care Act | 3 | 9.4% |
COVID-19 testing | 3 | 9.4% |
Child | 3 | 9.4% |
Clinical trial | 3 | 9.4% |
Competition (economics) | 3 | 9.4% |
Computer security | 3 | 9.4% |
Digital Single Market | 3 | 9.4% |
Dose (biochemistry) | 3 | 9.4% |
Drug | 3 | 9.4% |
Drugs acting on the nervous system | 3 | 9.4% |
Emergency department | 3 | 9.4% |
Fentanyl | 3 | 9.4% |
Governance | 3 | 9.4% |
Heroin | 3 | 9.4% |
Intensive care medicine | 3 | 9.4% |
Intensive care unit | 3 | 9.4% |
Medical prescription | 3 | 9.4% |
Medical treatments | 3 | 9.4% |
Methadone | 3 | 9.4% |
Morphine | 3 | 9.4% |
Nursing | 3 | 9.4% |
Obesity | 3 | 9.4% |
Oxycodone | 3 | 9.4% |
Pain | 3 | 9.4% |
Patient safety | 3 | 9.4% |
Pharmacology | 3 | 9.4% |
Physical therapy | 3 | 9.4% |
Prescription monitoring program | 3 | 9.4% |
Psychoactive drugs | 3 | 9.4% |
Quality of life | 3 | 9.4% |
Quarantine | 3 | 9.4% |
Screening (medicine) | 3 | 9.4% |
Severe acute respiratory syndrome coronavirus 2 | 3 | 9.4% |
Simulation | 3 | 9.4% |
Spanish flu | 3 | 9.4% |
Strategic planning | 3 | 9.4% |
Tax | 3 | 9.4% |
Telecommuting | 3 | 9.4% |
Adherence (medicine) | 2 | 6.2% |
Analgesic | 2 | 6.2% |
Artificial intelligence | 2 | 6.2% |
Automation | 2 | 6.2% |
Benzodiazepine | 2 | 6.2% |
Centrality | 2 | 6.2% |
Childbirth | 2 | 6.2% |
Circular economy | 2 | 6.2% |
Climate change mitigation | 2 | 6.2% |
Climate resilience | 2 | 6.2% |
Comorbidity | 2 | 6.2% |
Compartmental models in epidemiology | 2 | 6.2% |
Computer network | 2 | 6.2% |
Computing | 2 | 6.2% |
Correlation and dependence | 2 | 6.2% |
Cultural heritage | 2 | 6.2% |
Cyberattack | 2 | 6.2% |
Democracy | 2 | 6.2% |
Digital health | 2 | 6.2% |
Digital transformation | 2 | 6.2% |
Economic inequality | 2 | 6.2% |
Economics | 2 | 6.2% |
Education in France | 2 | 6.2% |
Emergency management | 2 | 6.2% |
Emerging technologies | 2 | 6.2% |
Empowerment | 2 | 6.2% |
Entrepreneurship | 2 | 6.2% |
Ethics | 2 | 6.2% |
Exponential distribution | 2 | 6.2% |
Gabapentin | 2 | 6.2% |
Gender | 2 | 6.2% |
Gender equality | 2 | 6.2% |
Generic drug | 2 | 6.2% |
Globalization | 2 | 6.2% |
Government | 2 | 6.2% |
Harm reduction | 2 | 6.2% |
Health care industry | 2 | 6.2% |
Health informatics | 2 | 6.2% |
Health professional | 2 | 6.2% |
Human migration | 2 | 6.2% |
Human trafficking | 2 | 6.2% |
Immigration | 2 | 6.2% |
Influenza A virus subtype H1N1 | 2 | 6.2% |
Influenza A virus subtype H3N2 | 2 | 6.2% |
Information | 2 | 6.2% |
Information privacy | 2 | 6.2% |
Internet of things | 2 | 6.2% |
Interoperability | 2 | 6.2% |
Labour economics | 2 | 6.2% |
Life expectancy | 2 | 6.2% |
Life-cycle assessment | 2 | 6.2% |
Major depressive disorder | 2 | 6.2% |
Market (economics) | 2 | 6.2% |
Materials science | 2 | 6.2% |
Medical diagnosis | 2 | 6.2% |
Medical guideline | 2 | 6.2% |
Medical test | 2 | 6.2% |
Meta-analysis | 2 | 6.2% |
Middle East respiratory syndrome | 2 | 6.2% |
Multiculturalism | 2 | 6.2% |
Neonatal withdrawal | 2 | 6.2% |
Non-communicable disease | 2 | 6.2% |
Open access | 2 | 6.2% |
Opiate | 2 | 6.2% |
Opioid epidemic | 2 | 6.2% |
Ordinary least squares | 2 | 6.2% |
Pain management | 2 | 6.2% |
Parameter | 2 | 6.2% |
Personalized medicine | 2 | 6.2% |
Pharmaceutical industry | 2 | 6.2% |
Pharmaceutical sciences | 2 | 6.2% |
Pharmacy | 2 | 6.2% |
Placebo | 2 | 6.2% |
Policy | 2 | 6.2% |
Pollution | 2 | 6.2% |
Precarity | 2 | 6.2% |
Privacy | 2 | 6.2% |
Productivity | 2 | 6.2% |
Progress | 2 | 6.2% |
Psychiatry | 2 | 6.2% |
Psychology | 2 | 6.2% |
Randomized controlled trial | 2 | 6.2% |
Regression analysis | 2 | 6.2% |
Resource | 2 | 6.2% |
Robotics | 2 | 6.2% |
Screening, brief intervention and referral to treatment | 2 | 6.2% |
Security | 2 | 6.2% |
Sensitivity and specificity | 2 | 6.2% |
Severe acute respiratory syndrome | 2 | 6.2% |
Social exclusion | 2 | 6.2% |
Society | 2 | 6.2% |
Spearman's rank correlation coefficient | 2 | 6.2% |
States of emergency in France | 2 | 6.2% |
Survey methodology | 2 | 6.2% |
Sustainable Development Goal 1 | 2 | 6.2% |
Sustainable Development Goal 13 | 2 | 6.2% |
Sustainable development | 2 | 6.2% |
Systematic review | 2 | 6.2% |
Technology | 2 | 6.2% |
Transmission (medicine) | 2 | 6.2% |
Vaccination | 2 | 6.2% |
2019–20 coronavirus outbreak | 1 | 3.1% |
2019–20 coronavirus pandemic | 1 | 3.1% |
2020 | 1 | 3.1% |
Abnormal psychology | 1 | 3.1% |
Abuse | 1 | 3.1% |
Accessibility | 1 | 3.1% |
Acne | 1 | 3.1% |
Adolescent health | 1 | 3.1% |
Advanced practice nurse | 1 | 3.1% |
Adverse effect | 1 | 3.1% |
African Americans | 1 | 3.1% |
Alex Azar | 1 | 3.1% |
Alprazolam | 1 | 3.1% |
Analytics | 1 | 3.1% |
Antidepressant | 1 | 3.1% |
Asthma | 1 | 3.1% |
Asylum seeker | 1 | 3.1% |
Audit | 1 | 3.1% |
Bank | 1 | 3.1% |
Baseline (budgeting) | 1 | 3.1% |
Basic reproduction number | 1 | 3.1% |
Behavioural sciences | 1 | 3.1% |
Benzodiazepine withdrawal syndrome | 1 | 3.1% |
Benzoyl peroxide | 1 | 3.1% |
Benzoyl peroxide/clindamycin | 1 | 3.1% |
Biosimilar | 1 | 3.1% |
Birth control | 1 | 3.1% |
Blinded experiment | 1 | 3.1% |
Bond (finance) | 1 | 3.1% |
Branches of science | 1 | 3.1% |
Breastfeeding | 1 | 3.1% |
Business | 1 | 3.1% |
COVID-19 pandemic in mainland China | 1 | 3.1% |
COVID-19 pandemic in the United Kingdom | 1 | 3.1% |
COVID-19 pandemic in the United States | 1 | 3.1% |
Caesarean section | 1 | 3.1% |
Cannabis (drug) | 1 | 3.1% |
Cardiovascular disease | 1 | 3.1% |
Census | 1 | 3.1% |
Chemicals in medicine | 1 | 3.1% |
Child support | 1 | 3.1% |
Chinese nobility | 1 | 3.1% |
Chronic pain | 1 | 3.1% |
Citalopram | 1 | 3.1% |
Climate change | 1 | 3.1% |
Clinical psychology | 1 | 3.1% |
Clomipramine | 1 | 3.1% |
Clonazepam | 1 | 3.1% |
Clonidine | 1 | 3.1% |
Cognition | 1 | 3.1% |
Cohort study | 1 | 3.1% |
Colorectal cancer | 1 | 3.1% |
Comedo | 1 | 3.1% |
Community | 1 | 3.1% |
Community health | 1 | 3.1% |
Comparative effectiveness research | 1 | 3.1% |
Competition (companies) | 1 | 3.1% |
Computer simulation | 1 | 3.1% |
Confidence interval | 1 | 3.1% |
Contact tracing | 1 | 3.1% |
Content validity | 1 | 3.1% |
Contract | 1 | 3.1% |
Coronavirus | 1 | 3.1% |
Corporate social responsibility | 1 | 3.1% |
Cost–benefit analysis | 1 | 3.1% |
Crisis management | 1 | 3.1% |
Cronbach's alpha | 1 | 3.1% |
Culture | 1 | 3.1% |
Cyberwarfare | 1 | 3.1% |
Database | 1 | 3.1% |
Death | 1 | 3.1% |
Deductible | 1 | 3.1% |
Dementia | 1 | 3.1% |
Demography | 1 | 3.1% |
Dependent and independent variables | 1 | 3.1% |
Developmental disability | 1 | 3.1% |
Diagnostic and Statistical Manual of Mental Disorders | 1 | 3.1% |
Dialysis | 1 | 3.1% |
Diazepam | 1 | 3.1% |
Digital literacy | 1 | 3.1% |
Disability | 1 | 3.1% |
Diseases and disorders | 1 | 3.1% |
Donald Trump | 1 | 3.1% |
Drug development | 1 | 3.1% |
Drug rehabilitation | 1 | 3.1% |
Drug withdrawal | 1 | 3.1% |
Eclampsia | 1 | 3.1% |
Economy of the United States | 1 | 3.1% |
Educational technology | 1 | 3.1% |
Eigenvalues and eigenvectors | 1 | 3.1% |
Electroconvulsive therapy | 1 | 3.1% |
Electronic cigarette | 1 | 3.1% |
Emergency | 1 | 3.1% |
Executive Order 12866 | 1 | 3.1% |
Executive Order 13813 | 1 | 3.1% |
Exercise | 1 | 3.1% |
Expert | 1 | 3.1% |
Exploratory factor analysis | 1 | 3.1% |
Extended-release morphine | 1 | 3.1% |
Face masks during the COVID-19 pandemic | 1 | 3.1% |
Factor analysis | 1 | 3.1% |
False positives and false negatives | 1 | 3.1% |
Federal Food, Drug, and Cosmetic Act | 1 | 3.1% |
Fee-for-service | 1 | 3.1% |
Fever | 1 | 3.1% |
Fibromyalgia | 1 | 3.1% |
Fluoxetine | 1 | 3.1% |
Foster care | 1 | 3.1% |
Gabapentinoid | 1 | 3.1% |
Geographic mobility | 1 | 3.1% |
Global health | 1 | 3.1% |
Global warming | 1 | 3.1% |
Great Depression | 1 | 3.1% |
Gross domestic product | 1 | 3.1% |
Gyeongsang Province | 1 | 3.1% |
Health care in the United States | 1 | 3.1% |
Health insurance coverage in the United States | 1 | 3.1% |
Health insurance marketplace | 1 | 3.1% |
Health literacy | 1 | 3.1% |
Health promotion | 1 | 3.1% |
Health technology | 1 | 3.1% |
Health technology in the United States | 1 | 3.1% |
Healthcare in Taiwan | 1 | 3.1% |
Hispanic and Latino Americans | 1 | 3.1% |
Homelessness | 1 | 3.1% |
Hospital bed | 1 | 3.1% |
Hospital readmission | 1 | 3.1% |
Human diseases and disorders | 1 | 3.1% |
Human pregnancy | 1 | 3.1% |
Human reproduction | 1 | 3.1% |
Hydrocodone | 1 | 3.1% |
Hypertension | 1 | 3.1% |
Hypertensive disease of pregnancy | 1 | 3.1% |
Hypnotic | 1 | 3.1% |
Incentive | 1 | 3.1% |
Infant | 1 | 3.1% |
Infant mortality | 1 | 3.1% |
Infectious diseases | 1 | 3.1% |
Influenza research | 1 | 3.1% |
Institution | 1 | 3.1% |
Interest rate | 1 | 3.1% |
International Statistical Classification of Diseases and Related Health Problems | 1 | 3.1% |
Intervention (counseling) | 1 | 3.1% |
Intrauterine device | 1 | 3.1% |
Isolation (health care) | 1 | 3.1% |
K-Quarantine | 1 | 3.1% |
Kidney failure | 1 | 3.1% |
Korea | 1 | 3.1% |
Kuder–Richardson Formula 20 | 1 | 3.1% |
Law | 1 | 3.1% |
Learning | 1 | 3.1% |
Learning management system | 1 | 3.1% |
Liability insurance | 1 | 3.1% |
Likert scale | 1 | 3.1% |
Long-acting reversible contraception | 1 | 3.1% |
Lorazepam | 1 | 3.1% |
Low back pain | 1 | 3.1% |
Macroeconomics | 1 | 3.1% |
Management of HIV/AIDS | 1 | 3.1% |
Management of depression | 1 | 3.1% |
Manufacturing | 1 | 3.1% |
Market liquidity | 1 | 3.1% |
Medical humanities | 1 | 3.1% |
Medicare Advantage | 1 | 3.1% |
Medicare Part D | 1 | 3.1% |
Medicinal chemistry | 1 | 3.1% |
Methamphetamine | 1 | 3.1% |
Middle East respiratory syndrome-related coronavirus | 1 | 3.1% |
Moclobemide | 1 | 3.1% |
Monoamine oxidase inhibitor | 1 | 3.1% |
Mood disorder | 1 | 3.1% |
Mortality rate | 1 | 3.1% |
Motherhood | 1 | 3.1% |
Naltrexone | 1 | 3.1% |
National Flood Insurance Program | 1 | 3.1% |
Natural disaster | 1 | 3.1% |
Natural environment | 1 | 3.1% |
Needs assessment | 1 | 3.1% |
Neuroscience | 1 | 3.1% |
New Deal | 1 | 3.1% |
Newborn screening | 1 | 3.1% |
Nursing home | 1 | 3.1% |
Obstetrical bleeding | 1 | 3.1% |
Obstetrics | 1 | 3.1% |
Opioid tapering | 1 | 3.1% |
Option (finance) | 1 | 3.1% |
Osteoarthritis | 1 | 3.1% |
Out-of-pocket expense | 1 | 3.1% |
Over-the-counter drug | 1 | 3.1% |
PID controller | 1 | 3.1% |
Partial correlation | 1 | 3.1% |
Patient Protection and Affordable Care Act | 1 | 3.1% |
Pearson correlation coefficient | 1 | 3.1% |
Peer review | 1 | 3.1% |
Peripheral neuropathy | 1 | 3.1% |
Personal protective equipment | 1 | 3.1% |
Pharmacist | 1 | 3.1% |
Pharmacy benefit management | 1 | 3.1% |
Phenobarbital | 1 | 3.1% |
Physical fitness | 1 | 3.1% |
Pimple | 1 | 3.1% |
Pneumonia | 1 | 3.1% |
Poly drug use | 1 | 3.1% |
Polymerase chain reaction | 1 | 3.1% |
Pool Re | 1 | 3.1% |
Positive and negative predictive values | 1 | 3.1% |
Postpartum period | 1 | 3.1% |
Pre-eclampsia | 1 | 3.1% |
Pre-existing condition | 1 | 3.1% |
Prediction | 1 | 3.1% |
Pregnancy | 1 | 3.1% |
Premium tax credit | 1 | 3.1% |
Prescription drug prices in the United States | 1 | 3.1% |
Price | 1 | 3.1% |
Pricing | 1 | 3.1% |
Primary care | 1 | 3.1% |
Prison | 1 | 3.1% |
Procurement | 1 | 3.1% |
Project Bioshield Act | 1 | 3.1% |
Psychiatric hospital | 1 | 3.1% |
Psychiatry-related fields | 1 | 3.1% |
Psychological resilience | 1 | 3.1% |
Psychosocial | 1 | 3.1% |
Psychotherapy | 1 | 3.1% |
Public health surveillance | 1 | 3.1% |
Public hospital | 1 | 3.1% |
Public services | 1 | 3.1% |
Public–private partnership | 1 | 3.1% |
Race (human categorization) | 1 | 3.1% |
Race and ethnicity in the United States Census | 1 | 3.1% |
Radicalization | 1 | 3.1% |
Rapid antigen test | 1 | 3.1% |
Rebate (marketing) | 1 | 3.1% |
Recession | 1 | 3.1% |
Recession shapes | 1 | 3.1% |
Record linkage | 1 | 3.1% |
Recovery approach | 1 | 3.1% |
Registered nurse | 1 | 3.1% |
Regulatory Flexibility Act | 1 | 3.1% |
Reinsurance | 1 | 3.1% |
Reliability (statistics) | 1 | 3.1% |
Risk management | 1 | 3.1% |
Ron Wyden | 1 | 3.1% |
Safety culture | 1 | 3.1% |
School | 1 | 3.1% |
Sedative | 1 | 3.1% |
Selective serotonin reuptake inhibitor | 1 | 3.1% |
Self-care | 1 | 3.1% |
Sepsis | 1 | 3.1% |
Serotonin–norepinephrine reuptake inhibitor | 1 | 3.1% |
Sertraline | 1 | 3.1% |
Services sector of the economy | 1 | 3.1% |
Sick leave | 1 | 3.1% |
Single-payer healthcare | 1 | 3.1% |
Social Security (United States) | 1 | 3.1% |
Social aspects of psychoactive drugs | 1 | 3.1% |
Social determinants of health | 1 | 3.1% |
Social programs | 1 | 3.1% |
South Korean won | 1 | 3.1% |
Statistics | 1 | 3.1% |
Stimulant | 1 | 3.1% |
Strategy | 1 | 3.1% |
Stroke | 1 | 3.1% |
Substance abuse prevention | 1 | 3.1% |
Substance dependence | 1 | 3.1% |
Sustainable Development Goal 12 | 1 | 3.1% |
Sustainable Development Goal 3 | 1 | 3.1% |
Sustainable Development Goal 4 | 1 | 3.1% |
Sustainable Development Goal 8 | 1 | 3.1% |
Sustainable Development Goal 9 | 1 | 3.1% |
Symptom | 1 | 3.1% |
Synergy | 1 | 3.1% |
Tapentadol | 1 | 3.1% |
Teacher | 1 | 3.1% |
Temperature | 1 | 3.1% |
Title X | 1 | 3.1% |
Tramadol | 1 | 3.1% |
Transcranial direct-current stimulation | 1 | 3.1% |
Transcranial magnetic stimulation | 1 | 3.1% |
Treaties of the European Union | 1 | 3.1% |
Treaty on the Functioning of the European Union | 1 | 3.1% |
Type 2 diabetes | 1 | 3.1% |
Type I and type II errors | 1 | 3.1% |
Unfunded mandate | 1 | 3.1% |
Universal health care | 1 | 3.1% |
Urinary incontinence | 1 | 3.1% |
Validity (statistics) | 1 | 3.1% |
Value-based pricing | 1 | 3.1% |
Varenicline | 1 | 3.1% |
Venlafaxine | 1 | 3.1% |
Violence | 1 | 3.1% |
Welfare | 1 | 3.1% |
Women's health | 1 | 3.1% |
Workers' compensation | 1 | 3.1% |
abs | rel | |
---|---|---|
Health | 39 | 95.1% |
Health care | 32 | 78.0% |
Medicine | 31 | 75.6% |
Disease | 23 | 56.1% |
Infection | 23 | 56.1% |
Risk | 23 | 56.1% |
Health sciences | 22 | 53.7% |
Economic growth | 18 | 43.9% |
Economy | 18 | 43.9% |
Human activities | 18 | 43.9% |
Preventive healthcare | 18 | 43.9% |
Disability | 17 | 41.5% |
Economic inequality | 17 | 41.5% |
Education | 17 | 41.5% |
Governance | 17 | 41.5% |
Research | 17 | 41.5% |
Epidemiology | 16 | 39.0% |
Health system | 16 | 39.0% |
Public health | 16 | 39.0% |
Social exclusion | 16 | 39.0% |
Sustainability | 16 | 39.0% |
Sustainable Development Goals | 16 | 39.0% |
Immigration | 15 | 36.6% |
Internet of things | 15 | 36.6% |
Science | 15 | 36.6% |
Clinical medicine | 14 | 34.1% |
Computer security | 14 | 34.1% |
Cultural heritage | 14 | 34.1% |
Cyberattack | 14 | 34.1% |
Democracy | 14 | 34.1% |
Digital transformation | 14 | 34.1% |
Entrepreneurship | 14 | 34.1% |
Evaluation | 14 | 34.1% |
Infrastructure | 14 | 34.1% |
Innovation | 14 | 34.1% |
Interoperability | 14 | 34.1% |
Open science | 14 | 34.1% |
Personalized medicine | 14 | 34.1% |
Politics | 14 | 34.1% |
Productivity | 14 | 34.1% |
Security | 14 | 34.1% |
Society | 14 | 34.1% |
Technology | 14 | 34.1% |
Artificial intelligence | 13 | 31.7% |
Climate change | 13 | 31.7% |
Gender | 13 | 31.7% |
Globalization | 13 | 31.7% |
Health informatics | 13 | 31.7% |
Medical specialties | 13 | 31.7% |
Ageing | 12 | 29.3% |
Antimicrobial resistance | 12 | 29.3% |
Circular economy | 12 | 29.3% |
Climate change mitigation | 12 | 29.3% |
Cloud computing | 12 | 29.3% |
Computing | 12 | 29.3% |
Emerging technologies | 12 | 29.3% |
Expert | 12 | 29.3% |
Gender equality | 12 | 29.3% |
Manufacturing | 12 | 29.3% |
Multiculturalism | 12 | 29.3% |
Privacy | 12 | 29.3% |
Quality of life | 12 | 29.3% |
Resource | 12 | 29.3% |
Robotics | 12 | 29.3% |
Sustainable Development Goal 9 | 12 | 29.3% |
Digital health | 11 | 26.8% |
Health technology | 11 | 26.8% |
Market (economics) | 11 | 26.8% |
Automation | 10 | 24.4% |
COVID-19 pandemic | 10 | 24.4% |
Chronic condition | 10 | 24.4% |
Computer network | 10 | 24.4% |
Culture | 10 | 24.4% |
European Union legislative procedure | 10 | 24.4% |
Health equity | 10 | 24.4% |
Sustainable Development Goal 3 | 10 | 24.4% |
Vaccine | 10 | 24.4% |
Climate resilience | 9 | 22.0% |
Human trafficking | 9 | 22.0% |
Non-communicable disease | 9 | 22.0% |
Policy | 9 | 22.0% |
Strategic planning | 9 | 22.0% |
Sustainable Development Goal 8 | 9 | 22.0% |
Sustainable development | 9 | 22.0% |
Competition (economics) | 8 | 19.5% |
Coronavirus disease 2019 | 8 | 19.5% |
Digital Single Market | 8 | 19.5% |
Human migration | 8 | 19.5% |
Information privacy | 8 | 19.5% |
Mental disorder | 8 | 19.5% |
Sustainable Development Goal 12 | 8 | 19.5% |
Sustainable Development Goal 4 | 8 | 19.5% |
Treaty on the Functioning of the European Union | 8 | 19.5% |
Welfare | 8 | 19.5% |
Empowerment | 7 | 17.1% |
Hospital | 7 | 17.1% |
Medical diagnosis | 7 | 17.1% |
Mental health | 7 | 17.1% |
Pandemic | 7 | 17.1% |
Sustainable Development Goal 16 | 7 | 17.1% |
Child | 6 | 14.6% |
Competition (companies) | 6 | 14.6% |
Health promotion | 6 | 14.6% |
Institution | 6 | 14.6% |
Medication | 6 | 14.6% |
Nanoelectronics | 6 | 14.6% |
Substance abuse | 6 | 14.6% |
Big data | 5 | 12.2% |
Branches of science | 5 | 12.2% |
Committee | 5 | 12.2% |
Diagnostic and Statistical Manual of Mental Disorders | 5 | 12.2% |
Europe | 5 | 12.2% |
Gross domestic product | 5 | 12.2% |
Health policy | 5 | 12.2% |
Low-carbon economy | 5 | 12.2% |
Opioid | 5 | 12.2% |
Patient | 5 | 12.2% |
Prescription drug | 5 | 12.2% |
Psychiatry | 5 | 12.2% |
Regression analysis | 5 | 12.2% |
Social inequality | 5 | 12.2% |
Substance use disorder | 5 | 12.2% |
Attention deficit hyperactivity disorder | 4 | 9.8% |
Buprenorphine | 4 | 9.8% |
Cancer | 4 | 9.8% |
Copernicus Programme | 4 | 9.8% |
Creative industries | 4 | 9.8% |
Dose (biochemistry) | 4 | 9.8% |
Drug overdose | 4 | 9.8% |
Drug rehabilitation | 4 | 9.8% |
Drugs | 4 | 9.8% |
Drugs acting on the nervous system | 4 | 9.8% |
Medicaid | 4 | 9.8% |
Medical treatments | 4 | 9.8% |
Methadone | 4 | 9.8% |
Naloxone | 4 | 9.8% |
Opioid use disorder | 4 | 9.8% |
Peer review | 4 | 9.8% |
Pharmacology | 4 | 9.8% |
Physical therapy | 4 | 9.8% |
Psychoactive drugs | 4 | 9.8% |
Psychological resilience | 4 | 9.8% |
Risk assessment | 4 | 9.8% |
Screening (medicine) | 4 | 9.8% |
Severe acute respiratory syndrome coronavirus 2 | 4 | 9.8% |
Social aspects of psychoactive drugs | 4 | 9.8% |
Transmission (medicine) | 4 | 9.8% |
Zoonosis | 4 | 9.8% |
Bipolar disorder | 3 | 7.3% |
COVID-19 testing | 3 | 7.3% |
Childbirth | 3 | 7.3% |
Clinical psychology | 3 | 7.3% |
Diseases and disorders | 3 | 7.3% |
Economics | 3 | 7.3% |
Emergency department | 3 | 7.3% |
Epidemic | 3 | 7.3% |
Fentanyl | 3 | 7.3% |
Harm reduction | 3 | 7.3% |
Health insurance | 3 | 7.3% |
Heroin | 3 | 7.3% |
Impulsivity | 3 | 7.3% |
Influenza | 3 | 7.3% |
Insurance | 3 | 7.3% |
Internet | 3 | 7.3% |
Labour economics | 3 | 7.3% |
Macroeconomics | 3 | 7.3% |
Major depressive disorder | 3 | 7.3% |
Materials science | 3 | 7.3% |
Medicare (United States) | 3 | 7.3% |
Methylphenidate | 3 | 7.3% |
Mortality rate | 3 | 7.3% |
Naltrexone | 3 | 7.3% |
Poverty | 3 | 7.3% |
Progress | 3 | 7.3% |
Psychiatrist | 3 | 7.3% |
Psychology | 3 | 7.3% |
Recession | 3 | 7.3% |
Severe acute respiratory syndrome | 3 | 7.3% |
Social distancing | 3 | 7.3% |
Therapy | 3 | 7.3% |
Violence | 3 | 7.3% |
Addiction | 2 | 4.9% |
Affordable Care Act | 2 | 4.9% |
Anxiety disorder | 2 | 4.9% |
BRCA mutation | 2 | 4.9% |
Basic reproduction number | 2 | 4.9% |
Behavioural sciences | 2 | 4.9% |
Borderline personality disorder | 2 | 4.9% |
COVID-19 pandemic in the United Kingdom | 2 | 4.9% |
COVID-19 vaccine | 2 | 4.9% |
Cardiovascular disease | 2 | 4.9% |
Caregiver | 2 | 4.9% |
Cognition | 2 | 4.9% |
Cognitive behavioral therapy | 2 | 4.9% |
Comorbidity | 2 | 4.9% |
Compartmental models in epidemiology | 2 | 4.9% |
Confounding | 2 | 4.9% |
Corporate social responsibility | 2 | 4.9% |
Correlation and dependence | 2 | 4.9% |
Dependent and independent variables | 2 | 4.9% |
Digital twin | 2 | 4.9% |
Electronic health record | 2 | 4.9% |
Employment | 2 | 4.9% |
Errors and residuals | 2 | 4.9% |
Evidence-based medicine | 2 | 4.9% |
Fee-for-service | 2 | 4.9% |
Financial crisis of 2007–2008 | 2 | 4.9% |
Forecasting | 2 | 4.9% |
Global health | 2 | 4.9% |
Health Insurance Portability and Accountability Act | 2 | 4.9% |
Health care in the United States | 2 | 4.9% |
Health insurance in the United States | 2 | 4.9% |
Health professional | 2 | 4.9% |
Health security | 2 | 4.9% |
Homelessness | 2 | 4.9% |
Human diseases and disorders | 2 | 4.9% |
Hypertension | 2 | 4.9% |
Infant | 2 | 4.9% |
International Health Regulations | 2 | 4.9% |
Likelihood function | 2 | 4.9% |
Managed care | 2 | 4.9% |
Medical prescription | 2 | 4.9% |
Medical test | 2 | 4.9% |
Methadone maintenance | 2 | 4.9% |
Middle East respiratory syndrome | 2 | 4.9% |
Mood disorder | 2 | 4.9% |
Natural disaster | 2 | 4.9% |
Natural environment | 2 | 4.9% |
Nursing | 2 | 4.9% |
Opioid epidemic in the United States | 2 | 4.9% |
Personality disorder | 2 | 4.9% |
Pharmaceutical sciences | 2 | 4.9% |
Pharmacy | 2 | 4.9% |
Photonics | 2 | 4.9% |
Positive psychology | 2 | 4.9% |
Prison | 2 | 4.9% |
Pseudoephedrine | 2 | 4.9% |
Psychiatry-related fields | 2 | 4.9% |
Psychotherapy | 2 | 4.9% |
Public services | 2 | 4.9% |
Radicalization | 2 | 4.9% |
Reference range | 2 | 4.9% |
Sampling (statistics) | 2 | 4.9% |
Schizoaffective disorder | 2 | 4.9% |
Schizophrenia | 2 | 4.9% |
Sibling | 2 | 4.9% |
Signs and symptoms | 2 | 4.9% |
Social Security (United States) | 2 | 4.9% |
Social innovation | 2 | 4.9% |
Social issues | 2 | 4.9% |
Social programs | 2 | 4.9% |
Social work | 2 | 4.9% |
Substance-related disorders | 2 | 4.9% |
Synergy | 2 | 4.9% |
Tax | 2 | 4.9% |
2009 swine flu pandemic | 1 | 2.4% |
API | 1 | 2.4% |
Abnormal psychology | 1 | 2.4% |
Abortion | 1 | 2.4% |
Abstinence | 1 | 2.4% |
Abuse | 1 | 2.4% |
Academic degree | 1 | 2.4% |
Adult attention deficit hyperactivity disorder | 1 | 2.4% |
Aggregate demand | 1 | 2.4% |
Agriculture | 1 | 2.4% |
Air pollution | 1 | 2.4% |
Analgesic | 1 | 2.4% |
Antipsychotic | 1 | 2.4% |
Anxiety | 1 | 2.4% |
Applied mathematics | 1 | 2.4% |
Applied psychology | 1 | 2.4% |
Arrhythmia | 1 | 2.4% |
Artificial neural network | 1 | 2.4% |
Atomoxetine | 1 | 2.4% |
Attention deficit hyperactivity disorder management | 1 | 2.4% |
Attention deficit hyperactivity disorder predominantly inattentive | 1 | 2.4% |
Autism spectrum | 1 | 2.4% |
Balance of payments | 1 | 2.4% |
Bank | 1 | 2.4% |
Blood pressure | 1 | 2.4% |
COVID-19 | 1 | 2.4% |
COVID-19 lockdowns | 1 | 2.4% |
Caesarean section | 1 | 2.4% |
Carbon dioxide | 1 | 2.4% |
Cardiac arrest | 1 | 2.4% |
Cardiology | 1 | 2.4% |
Care work | 1 | 2.4% |
Case management (US healthcare system) | 1 | 2.4% |
Chatbot | 1 | 2.4% |
Chemicals in medicine | 1 | 2.4% |
Child abuse | 1 | 2.4% |
Child mortality | 1 | 2.4% |
Chronic fatigue syndrome | 1 | 2.4% |
Chronic pain | 1 | 2.4% |
Classification of mental disorders | 1 | 2.4% |
Clinic | 1 | 2.4% |
Clonidine | 1 | 2.4% |
Coefficient of determination | 1 | 2.4% |
Cognitive science | 1 | 2.4% |
Cohort study | 1 | 2.4% |
Community health | 1 | 2.4% |
Community mental health service | 1 | 2.4% |
Confidence interval | 1 | 2.4% |
Contact tracing | 1 | 2.4% |
Contract | 1 | 2.4% |
Convidecia | 1 | 2.4% |
Convolutional neural network | 1 | 2.4% |
CoronaVac | 1 | 2.4% |
Coronary artery disease | 1 | 2.4% |
Cousin | 1 | 2.4% |
Covaxin | 1 | 2.4% |
Creative Commons license | 1 | 2.4% |
Crisis management | 1 | 2.4% |
Critical thinking | 1 | 2.4% |
DSM-5 | 1 | 2.4% |
Data | 1 | 2.4% |
Debt | 1 | 2.4% |
Deep learning | 1 | 2.4% |
Density | 1 | 2.4% |
Depression (mood) | 1 | 2.4% |
Developed country | 1 | 2.4% |
Developing country | 1 | 2.4% |
Dextroamphetamine | 1 | 2.4% |
Diagnosis of schizophrenia | 1 | 2.4% |
Disease outbreak | 1 | 2.4% |
Dispatcher | 1 | 2.4% |
Drug test | 1 | 2.4% |
Drug utilization review | 1 | 2.4% |
Drug withdrawal | 1 | 2.4% |
Econometrics | 1 | 2.4% |
Economic equilibrium | 1 | 2.4% |
Economic recovery | 1 | 2.4% |
Educational technology | 1 | 2.4% |
Effect size | 1 | 2.4% |
Emergency Use Authorization | 1 | 2.4% |
Emergency management | 1 | 2.4% |
Emergency medicine | 1 | 2.4% |
Emerging market | 1 | 2.4% |
Emotional dysregulation | 1 | 2.4% |
Environmental, social and corporate governance | 1 | 2.4% |
Epilepsy | 1 | 2.4% |
Eviction | 1 | 2.4% |
Executive Order 12866 | 1 | 2.4% |
Extended-release morphine | 1 | 2.4% |
Families First Coronavirus Response Act | 1 | 2.4% |
Fiscal policy | 1 | 2.4% |
Fixed effects model | 1 | 2.4% |
Foreclosure | 1 | 2.4% |
Gabapentin | 1 | 2.4% |
Gender pay gap | 1 | 2.4% |
General practitioner | 1 | 2.4% |
Generalized anxiety disorder | 1 | 2.4% |
Gestational age | 1 | 2.4% |
Global Outbreak Alert and Response Network | 1 | 2.4% |
Government | 1 | 2.4% |
Great Recession | 1 | 2.4% |
Greenhouse gas | 1 | 2.4% |
Greenland ice sheet | 1 | 2.4% |
Guanfacine | 1 | 2.4% |
Health care prices in the United States | 1 | 2.4% |
Health economics | 1 | 2.4% |
Health insurance marketplace | 1 | 2.4% |
Heart | 1 | 2.4% |
Heart rate | 1 | 2.4% |
Hepatitis | 1 | 2.4% |
Hepatitis B | 1 | 2.4% |
Hepatitis C | 1 | 2.4% |
Hepatocellular carcinoma | 1 | 2.4% |
Herd immunity | 1 | 2.4% |
High-risk pregnancy | 1 | 2.4% |
Home birth | 1 | 2.4% |
Hypotension | 1 | 2.4% |
Immunology | 1 | 2.4% |
Improving Access to Psychological Therapies | 1 | 2.4% |
Imputation (statistics) | 1 | 2.4% |
Incarceration in the United States | 1 | 2.4% |
Incidence (epidemiology) | 1 | 2.4% |
Income | 1 | 2.4% |
Income distribution | 1 | 2.4% |
Infant mortality | 1 | 2.4% |
Infection prevention and control | 1 | 2.4% |
Insomnia | 1 | 2.4% |
Institutional racism | 1 | 2.4% |
Instrumental variables estimation | 1 | 2.4% |
Intellectual disability | 1 | 2.4% |
International Classification of Diseases | 1 | 2.4% |
Isolation (health care) | 1 | 2.4% |
Issues in ethics | 1 | 2.4% |
Janssen COVID-19 vaccine | 1 | 2.4% |
K-Quarantine | 1 | 2.4% |
Landlord | 1 | 2.4% |
Latin America | 1 | 2.4% |
Lease | 1 | 2.4% |
Least squares | 1 | 2.4% |
Life sciences | 1 | 2.4% |
Life-cycle assessment | 1 | 2.4% |
Lineage B.1.1.7 | 1 | 2.4% |
Lisdexamfetamine | 1 | 2.4% |
Logistic regression | 1 | 2.4% |
Long COVID | 1 | 2.4% |
Machine learning | 1 | 2.4% |
Mania | 1 | 2.4% |
Master of Social Work | 1 | 2.4% |
Maternal death | 1 | 2.4% |
Mathematical modelling of infectious disease | 1 | 2.4% |
Mathematical optimization | 1 | 2.4% |
Medi-Cal | 1 | 2.4% |
Median | 1 | 2.4% |
Medical home | 1 | 2.4% |
Medical record | 1 | 2.4% |
Medical statistics | 1 | 2.4% |
Mental Health Act 1983 | 1 | 2.4% |
Mental and behavioural disorders | 1 | 2.4% |
Mental disorders | 1 | 2.4% |
Meta-analysis | 1 | 2.4% |
Midwife | 1 | 2.4% |
Midwifery | 1 | 2.4% |
Minimum wage | 1 | 2.4% |
Moderna COVID-19 vaccine | 1 | 2.4% |
Molecular diagnostics | 1 | 2.4% |
Monetary policy | 1 | 2.4% |
Morphine | 1 | 2.4% |
Motivational interviewing | 1 | 2.4% |
Multisystem inflammatory syndrome in children | 1 | 2.4% |
Needle and syringe programmes | 1 | 2.4% |
Neonatal intensive care unit | 1 | 2.4% |
Neonatal withdrawal | 1 | 2.4% |
Nervous system | 1 | 2.4% |
Neuroscience | 1 | 2.4% |
New Deal | 1 | 2.4% |
Non-governmental organization | 1 | 2.4% |
Numeracy | 1 | 2.4% |
Obesity | 1 | 2.4% |
Opiate | 1 | 2.4% |
Opioid epidemic | 1 | 2.4% |
Option (finance) | 1 | 2.4% |
Oxfordshire | 1 | 2.4% |
Oxford–AstraZeneca COVID-19 vaccine | 1 | 2.4% |
Oxycodone | 1 | 2.4% |
P-value | 1 | 2.4% |
PHQ-9 | 1 | 2.4% |
Pain | 1 | 2.4% |
Pain management | 1 | 2.4% |
Palpitations | 1 | 2.4% |
Pearson correlation coefficient | 1 | 2.4% |
Pfizer–BioNTech COVID-19 vaccine | 1 | 2.4% |
Pharmacy benefit management | 1 | 2.4% |
Phenobarbital | 1 | 2.4% |
Plague of Justinian | 1 | 2.4% |
Pneumonia | 1 | 2.4% |
Polymerase chain reaction | 1 | 2.4% |
Population | 1 | 2.4% |
Positive and negative predictive values | 1 | 2.4% |
Post-traumatic stress disorder | 1 | 2.4% |
Postpartum period | 1 | 2.4% |
Precipitation | 1 | 2.4% |
Precision and recall | 1 | 2.4% |
Prediction | 1 | 2.4% |
Pregnancy | 1 | 2.4% |
Premium tax credit | 1 | 2.4% |
Prenatal care | 1 | 2.4% |
Prenatal development | 1 | 2.4% |
Preterm birth | 1 | 2.4% |
Primary care | 1 | 2.4% |
Psychiatric diagnosis | 1 | 2.4% |
Psychiatric diseases and disorders | 1 | 2.4% |
Psychiatric hospital | 1 | 2.4% |
Psychological trauma | 1 | 2.4% |
Psychopathology | 1 | 2.4% |
Psychosis | 1 | 2.4% |
Public Health Emergency of International Concern | 1 | 2.4% |
Public sphere | 1 | 2.4% |
Public–private partnership | 1 | 2.4% |
Purchasing power parity | 1 | 2.4% |
QT interval | 1 | 2.4% |
Qualifications for professional social work | 1 | 2.4% |
Quarantine | 1 | 2.4% |
RNA-dependent RNA polymerase | 1 | 2.4% |
Race (human categorization) | 1 | 2.4% |
Race and ethnicity in the United States Census | 1 | 2.4% |
Racial segregation in the United States | 1 | 2.4% |
Racing thoughts | 1 | 2.4% |
Racism | 1 | 2.4% |
Randomized controlled trial | 1 | 2.4% |
Rational emotive behavior therapy | 1 | 2.4% |
ReCAPTCHA | 1 | 2.4% |
Real-time polymerase chain reaction | 1 | 2.4% |
Receiver operating characteristic | 1 | 2.4% |
Recovery model | 1 | 2.4% |
Redistribution of income and wealth | 1 | 2.4% |
Regulatory Flexibility Act | 1 | 2.4% |
Regulatory compliance | 1 | 2.4% |
Renting | 1 | 2.4% |
Reparations for slavery | 1 | 2.4% |
Reproductive health | 1 | 2.4% |
Reverse transcription polymerase chain reaction | 1 | 2.4% |
Robust statistics | 1 | 2.4% |
Scatter plot | 1 | 2.4% |
Sea ice | 1 | 2.4% |
Sea level rise | 1 | 2.4% |
Self-care | 1 | 2.4% |
Sensitivity and specificity | 1 | 2.4% |
Serious mental illness | 1 | 2.4% |
Seroconversion | 1 | 2.4% |
Sex trafficking | 1 | 2.4% |
Sick leave | 1 | 2.4% |
Sinopharm BIBP COVID-19 vaccine | 1 | 2.4% |
Slavery | 1 | 2.4% |
Sleep | 1 | 2.4% |
Sleep disorder | 1 | 2.4% |
Smart city | 1 | 2.4% |
Social Security Disability Insurance | 1 | 2.4% |
Social stigma | 1 | 2.4% |
Societal racism | 1 | 2.4% |
Somatic symptom disorder | 1 | 2.4% |
Spanish flu | 1 | 2.4% |
Sputnik V COVID-19 vaccine | 1 | 2.4% |
Startup company | 1 | 2.4% |
Statistical classification | 1 | 2.4% |
Statistical hypothesis testing | 1 | 2.4% |
Statistics | 1 | 2.4% |
Stay-at-home order | 1 | 2.4% |
Stimulant | 1 | 2.4% |
Subprime mortgage crisis | 1 | 2.4% |
Substance dependence | 1 | 2.4% |
Supplemental Security Income | 1 | 2.4% |
Support-vector machine | 1 | 2.4% |
Symptom | 1 | 2.4% |
Symptoms of COVID-19 | 1 | 2.4% |
Syncope (medicine) | 1 | 2.4% |
Systematic review | 1 | 2.4% |
Teenage pregnancy | 1 | 2.4% |
Telehealth | 1 | 2.4% |
Trade | 1 | 2.4% |
Trans man | 1 | 2.4% |
Trans woman | 1 | 2.4% |
Travel visa | 1 | 2.4% |
Tropical cyclone | 1 | 2.4% |
Unemployment | 1 | 2.4% |
Unfunded mandate | 1 | 2.4% |
Unpaid work | 1 | 2.4% |
Venlafaxine | 1 | 2.4% |
Virus | 1 | 2.4% |
WIC | 1 | 2.4% |
Wealth | 1 | 2.4% |
Woman | 1 | 2.4% |
Women's health | 1 | 2.4% |
Workers' compensation | 1 | 2.4% |
abs | rel | |
---|---|---|
Health | 7 | 100.0% |
Health care | 7 | 100.0% |
Health sciences | 7 | 100.0% |
Medicine | 7 | 100.0% |
Chronic condition | 5 | 71.4% |
Hospital | 5 | 71.4% |
Risk | 5 | 71.4% |
Social determinants of health | 5 | 71.4% |
Comorbidity | 4 | 57.1% |
Disease | 4 | 57.1% |
Health system | 4 | 57.1% |
Infection | 4 | 57.1% |
Medical specialties | 4 | 57.1% |
Naloxone | 4 | 57.1% |
Opioid | 4 | 57.1% |
Preventive healthcare | 4 | 57.1% |
Public health | 4 | 57.1% |
Substance abuse | 4 | 57.1% |
Substance use disorder | 4 | 57.1% |
Abuse | 3 | 42.9% |
Adherence (medicine) | 3 | 42.9% |
Adolescence | 3 | 42.9% |
Adverse effect | 3 | 42.9% |
Ageing | 3 | 42.9% |
Alcoholism | 3 | 42.9% |
Amitriptyline | 3 | 42.9% |
Antidepressant | 3 | 42.9% |
Antipsychotic | 3 | 42.9% |
Anxiety disorder | 3 | 42.9% |
Branches of science | 3 | 42.9% |
Buprenorphine | 3 | 42.9% |
COVID-19 pandemic | 3 | 42.9% |
Caregiver | 3 | 42.9% |
Child | 3 | 42.9% |
Child abuse | 3 | 42.9% |
Childbirth | 3 | 42.9% |
Clinical medicine | 3 | 42.9% |
Cognitive behavioral therapy | 3 | 42.9% |
Cognitive disorder | 3 | 42.9% |
Community health | 3 | 42.9% |
Community health worker | 3 | 42.9% |
Dementia | 3 | 42.9% |
Depression (mood) | 3 | 42.9% |
Disability | 3 | 42.9% |
Diseases and disorders | 3 | 42.9% |
Drug | 3 | 42.9% |
Evidence-based medicine | 3 | 42.9% |
Gender | 3 | 42.9% |
HIV-associated neurocognitive disorder | 3 | 42.9% |
HIV/AIDS | 3 | 42.9% |
Harm reduction | 3 | 42.9% |
Health professional | 3 | 42.9% |
Health promotion | 3 | 42.9% |
Hepatitis | 3 | 42.9% |
Homelessness | 3 | 42.9% |
Interpersonal psychotherapy | 3 | 42.9% |
Major depressive disorder | 3 | 42.9% |
Management of HIV/AIDS | 3 | 42.9% |
Mental disorder | 3 | 42.9% |
Mental distress | 3 | 42.9% |
Mental health | 3 | 42.9% |
Neurology | 3 | 42.9% |
Opioid overdose | 3 | 42.9% |
Opioid use disorder | 3 | 42.9% |
Parenting | 3 | 42.9% |
Peer support | 3 | 42.9% |
Pre-exposure prophylaxis | 3 | 42.9% |
Prenatal development | 3 | 42.9% |
Prevention of HIV/AIDS | 3 | 42.9% |
Primary health care | 3 | 42.9% |
Psychiatry | 3 | 42.9% |
Psychology | 3 | 42.9% |
Psychosis | 3 | 42.9% |
Psychosocial | 3 | 42.9% |
Psychotherapy | 3 | 42.9% |
Recovery model | 3 | 42.9% |
Research | 3 | 42.9% |
Screening (medicine) | 3 | 42.9% |
Self-care | 3 | 42.9% |
Self-harm | 3 | 42.9% |
Sertraline | 3 | 42.9% |
Sex work | 3 | 42.9% |
Sex worker | 3 | 42.9% |
Social exclusion | 3 | 42.9% |
Social stigma | 3 | 42.9% |
Social work | 3 | 42.9% |
Substance dependence | 3 | 42.9% |
Suicide | 3 | 42.9% |
Suicide prevention | 3 | 42.9% |
Therapy | 3 | 42.9% |
Trazodone | 3 | 42.9% |
Tuberculosis | 3 | 42.9% |
Venlafaxine | 3 | 42.9% |
Violence | 3 | 42.9% |
Woman | 3 | 42.9% |
Youth | 3 | 42.9% |
Anxiety | 2 | 28.6% |
COVID-19 | 2 | 28.6% |
Electronic health record | 2 | 28.6% |
HIV/AIDS in Africa | 2 | 28.6% |
Health equity | 2 | 28.6% |
Medication | 2 | 28.6% |
Non-communicable disease | 2 | 28.6% |
Pandemic | 2 | 28.6% |
Psychiatric and mental health nursing | 2 | 28.6% |
Psychiatric rehabilitation | 2 | 28.6% |
Regression analysis | 2 | 28.6% |
Reproductive health | 2 | 28.6% |
Black people | 1 | 14.3% |
Booster dose | 1 | 14.3% |
British Bangladeshis | 1 | 14.3% |
British Pakistanis | 1 | 14.3% |
COVID-19 pandemic in Mexico | 1 | 14.3% |
COVID-19 vaccination in Malaysia | 1 | 14.3% |
COVID-19 vaccine | 1 | 14.3% |
Cardiovascular disease | 1 | 14.3% |
Causes of death | 1 | 14.3% |
Census | 1 | 14.3% |
Classification of ethnicity in the United Kingdom | 1 | 14.3% |
Clinical trial | 1 | 14.3% |
Contact tracing | 1 | 14.3% |
Correlation | 1 | 14.3% |
Data analysis | 1 | 14.3% |
Data and information visualization | 1 | 14.3% |
Death | 1 | 14.3% |
Demography | 1 | 14.3% |
Digital contact tracing | 1 | 14.3% |
Drug injection | 1 | 14.3% |
Drug overdose | 1 | 14.3% |
Education | 1 | 14.3% |
Epidemiology | 1 | 14.3% |
Epidemiology of HIV/AIDS | 1 | 14.3% |
Ethnic group | 1 | 14.3% |
Geographic information system | 1 | 14.3% |
Geomatics | 1 | 14.3% |
Hazard ratio | 1 | 14.3% |
Health economics | 1 | 14.3% |
Health informatics | 1 | 14.3% |
Health policy | 1 | 14.3% |
Immunization | 1 | 14.3% |
Interoperability | 1 | 14.3% |
Linear regression | 1 | 14.3% |
Maternal death | 1 | 14.3% |
Maternal health | 1 | 14.3% |
Medicaid | 1 | 14.3% |
Medicare (United States) | 1 | 14.3% |
Mental health nursing | 1 | 14.3% |
Mortality rate | 1 | 14.3% |
Multicollinearity | 1 | 14.3% |
Occupational safety and health | 1 | 14.3% |
Outcomes research | 1 | 14.3% |
Pearson correlation coefficient | 1 | 14.3% |
Poverty | 1 | 14.3% |
Principal component analysis | 1 | 14.3% |
Privacy | 1 | 14.3% |
Public services | 1 | 14.3% |
Sexual and reproductive health | 1 | 14.3% |
Social programs | 1 | 14.3% |
Socioeconomic status | 1 | 14.3% |
Spatial analysis | 1 | 14.3% |
Statistics | 1 | 14.3% |
Survival analysis | 1 | 14.3% |
White British | 1 | 14.3% |
abs | rel | |
---|---|---|
Disease | 2 | 100.0% |
Employment | 2 | 100.0% |
Health | 2 | 100.0% |
Health care | 2 | 100.0% |
Health sciences | 2 | 100.0% |
Health system | 2 | 100.0% |
Hospital | 2 | 100.0% |
Human activities | 2 | 100.0% |
Infection | 2 | 100.0% |
Medicine | 2 | 100.0% |
Preventive healthcare | 2 | 100.0% |
Public health | 2 | 100.0% |
Risk | 2 | 100.0% |
Alcoholism | 1 | 50.0% |
Bank | 1 | 50.0% |
Birth defect | 1 | 50.0% |
Body mass index | 1 | 50.0% |
Bond (finance) | 1 | 50.0% |
Breastfeeding | 1 | 50.0% |
COVID-19 pandemic | 1 | 50.0% |
COVID-19 pandemic in the United Kingdom | 1 | 50.0% |
COVID-19 testing | 1 | 50.0% |
Cancer | 1 | 50.0% |
Cardiovascular disease | 1 | 50.0% |
Childbirth | 1 | 50.0% |
Chronic condition | 1 | 50.0% |
Clinical medicine | 1 | 50.0% |
Crisis management | 1 | 50.0% |
Death | 1 | 50.0% |
Digital literacy | 1 | 50.0% |
Diseases and disorders | 1 | 50.0% |
Economic growth | 1 | 50.0% |
Economy | 1 | 50.0% |
Education | 1 | 50.0% |
Educational technology | 1 | 50.0% |
Electronic health record | 1 | 50.0% |
Epidemic | 1 | 50.0% |
Evidence-based medicine | 1 | 50.0% |
Fair Labor Standards Act of 1938 | 1 | 50.0% |
Family and Medical Leave Act of 1993 | 1 | 50.0% |
Gestational age | 1 | 50.0% |
Gestational diabetes | 1 | 50.0% |
Governance | 1 | 50.0% |
Great Depression | 1 | 50.0% |
Gyeongsang Province | 1 | 50.0% |
HIV/AIDS | 1 | 50.0% |
Health economics | 1 | 50.0% |
Health equity | 1 | 50.0% |
Health insurance | 1 | 50.0% |
Health policy | 1 | 50.0% |
Health professional | 1 | 50.0% |
Healthcare Cost and Utilization Project | 1 | 50.0% |
Healthcare in Taiwan | 1 | 50.0% |
Hospital bed | 1 | 50.0% |
Human development | 1 | 50.0% |
Human pregnancy | 1 | 50.0% |
Human reproduction | 1 | 50.0% |
Hypertension | 1 | 50.0% |
Hypertensive disease of pregnancy | 1 | 50.0% |
Infant mortality | 1 | 50.0% |
Insurance | 1 | 50.0% |
Intensive care medicine | 1 | 50.0% |
Intensive care unit | 1 | 50.0% |
Interest rate | 1 | 50.0% |
International Classification of Diseases | 1 | 50.0% |
K-Quarantine | 1 | 50.0% |
Kidney failure | 1 | 50.0% |
Korea | 1 | 50.0% |
Large for gestational age | 1 | 50.0% |
Learning | 1 | 50.0% |
Learning management system | 1 | 50.0% |
Market liquidity | 1 | 50.0% |
Maternal death | 1 | 50.0% |
Maternal health | 1 | 50.0% |
Maternal mortality in the United States | 1 | 50.0% |
Maternal–fetal medicine | 1 | 50.0% |
Medicaid | 1 | 50.0% |
Medical humanities | 1 | 50.0% |
Medical specialties | 1 | 50.0% |
Mental disorder | 1 | 50.0% |
Mental health | 1 | 50.0% |
Middle East respiratory syndrome | 1 | 50.0% |
Mortality rate | 1 | 50.0% |
Motherhood | 1 | 50.0% |
New Deal | 1 | 50.0% |
Nursing | 1 | 50.0% |
Obesity | 1 | 50.0% |
Obstetrics | 1 | 50.0% |
Pandemic | 1 | 50.0% |
Parental leave | 1 | 50.0% |
Patient | 1 | 50.0% |
Postpartum period | 1 | 50.0% |
Pre-eclampsia | 1 | 50.0% |
Pregnancy | 1 | 50.0% |
Prenatal care | 1 | 50.0% |
Preterm birth | 1 | 50.0% |
Public hospital | 1 | 50.0% |
Public services | 1 | 50.0% |
Quarantine | 1 | 50.0% |
Recession | 1 | 50.0% |
Research | 1 | 50.0% |
School | 1 | 50.0% |
Severe acute respiratory syndrome coronavirus 2 | 1 | 50.0% |
Social determinants of health | 1 | 50.0% |
Social distancing | 1 | 50.0% |
Social programs | 1 | 50.0% |
South Korean won | 1 | 50.0% |
Stroke | 1 | 50.0% |
Substance abuse | 1 | 50.0% |
Substance use disorder | 1 | 50.0% |
Tax | 1 | 50.0% |
Teacher | 1 | 50.0% |
Telehealth | 1 | 50.0% |
Type 2 diabetes | 1 | 50.0% |
Universal health care | 1 | 50.0% |
WIC | 1 | 50.0% |
Woman | 1 | 50.0% |
Women's health | 1 | 50.0% |